MOL #111583

Restoration of physiological expression of 5-HT₆ into the primary cilia of null

mutant neurons lengthens both primary cilia and dendrites.

Atom J. Lesiak, Matthew Brodsky, Nathalie Cohenca, Alexandra G. Croicu, and John F.

Neumaier

Department of Psychiatry and Behavioral Science, Department of Pharmacology,

University of Washington, Seattle, WA 98104

5-HT6R Rescue Lengthens Primary Cilia and Dendritic Length

*Corresponding author at:

Department of Psychiatry and Behavioral Sciences, University of Washington,

Harborview Medical Center, Box 359911, 325 9th Avenue, Seattle, WA 98104, USA.

Tel.: +1 206 897 5803; fax: +1 206 897 5804.

E-mail address: neumaier@uw.edu (John F. Neumaier).

of text pages: 39

- # of Tables: 0
- # of Figures: 6
- # of References: 60
- # of Words in Abstract: 240
- # of Words in Introduction: 782
- # of Words in Discussion: 1340
- List of nonstandard abbreviations
- CNS Central Nervous System
- GPCR G-protein Coupled Receptor
- DIV Day in Vitro
- NBA Neurobasal A
- GM Growth Medium
- WT Wildtype
- PFA/PHEMS Paraformaldehyde/PIPES, HEPES, EGTA, MgCl₂ buffer
- EV Empty Vector
- HA Hemagglutinin

MOL #111583

Abstract

5-HT₆ serotonin receptors are promising targets for a variety of neuropsychiatric disorders and have been linked to several cellular signaling cascades. Endogenous 5-HT₆ receptors are restricted to the primary neuronal cilium, a small sensory organelle stemming from the cell body that receives numerous extra-synaptic signals. Inhibition of $5-HT_6$ receptors decreases cilia length in primary neuronal cultures, but the signaling mechanisms involved are still unclear. Intense overexpression of exogenous 5-HT₆ receptors increases the likelihood for receptors to localize outside of the primary cilium and have been associated with changes in cilia morphology and dendritic outgrowth. In the present study, we explore the role of 5-HT₆R rescue on neuronal morphology in primary neuronal cultures from 5-HT₆R-KO mice, while maintaining a more physiological level of expression, wherein the receptor localizes to cilia in 80-90% of neurons (similar to endogenous 5-HT₆R localization). We found that rescue of 5-HT₆R expression is sufficient to increase cilia length and dendritic outgrowth, but primarily in neurons in which the receptor is located exclusively in the primary cilia. Additionally, we found that expression of 5-HT₆R mutants, deficient in agonist-stimulated cAMP or without the predicted Fyn kinase binding domain, maintain constitutive activity for stimulating cAMP and still increased the length of cilia, while the proposed Fyn kinase domain was required for stimulating dendritic outgrowth. These findings highlight the complexity of 5-HT₆R function and localization, particularly when using exogenous overexpression, and provide greater understanding and potential mechanisms for 5-HT₆R drug therapies.

Introduction

The 5-HT₆ serotonin receptor (5-HT₆R) is a promising target to treat a variety of neurological and cognitive disorders, including cognitive impairment, Parkinson's, Alzheimer's, obesity, schizophrenia, motor disorders, sleep, and depression (Mitchell and Neumaier, 2005; Hirst et al., 2006; Wesolowska and Nikiforuk, 2007; Ferguson et al., 2008; King et al., 2008; Morairty et al., 2008; Arnt et al., 2010; Carr et al., 2010; Meffre et al., 2012; MW J de Bruin and G Kruse, 2015; Aldrin-Kirk et al., 2016; Brodsky et al., 2016). Despite mounting evidence for the therapeutic value of this receptor, little is known about the specific mechanisms underlying 5-HT₆R signaling. 5-HT₆R is expressed nearly exclusively in CNS, in a limited number of brain regions including cortex, hippocampus, and most abundantly in the striatum (East et al., 2002; Hirst et al., 2003; Brodsky et al., 2017); however, localization of 5-HT₆R in vivo is notoriously difficult because commercially available antibodies with sufficient specificity have been inconsistently available. Additionally, the subcellular localization of the receptor can be easily overlooked because 5-HT₆R is the only serotonin receptor that localizes to the primary neuronal cilium (Brailov et al., 2000; Berbari et al., 2008; Domire and Mykytyn, 2009; Brodsky et al., 2017; Hu et al., 2017).

Primary cilia were described over a century ago and are ubiquitous to almost all non-dividing mammalian cells, including neurons, yet these singular non-motile appendages were frequently misinterpreted as vestigial organelles until recently (Fuchs and Schwark, 2004; Louvi and Grove, 2011). Now the primary cilium is recognized as an important regulator of cellular function by acting as a "cellular antenna", sensing extracellular signals in the extra-synaptic environment (Singla, 2006; Green and

Mykytyn, 2014). Trafficking of specific proteins into primary cilia is strictly regulated by the basal body and involves active transport along the central microtubule doublet that provides the cilia structure (Pazour and Bloodgood, 2008; Louvi and Grove, 2011; Stepanek and Pigino, 2016). Disruption of primary cilia function is linked with a variety of disorders termed ciliopathies, such as Bardet Biedl Syndrome, polycystic kidney disorder, polydactyly, hydrocephalus, obesity, disrupted neurogenesis, and cognitive disorders (Louvi and Grove, 2011; Lee and Gleeson, 2011; Valente *et al.*, 2013; Gazea *et al.*, 2016; Trulioff *et al.*, 2017; Schmidt *et al.*, 2017).

Shortly after the cloning and identification of 5-HT₆Rs, expression of 5-HT₆Rs was reported to be faintly scattered throughout dendrites particularly in striatum, but soon it was recognized that 5-HT₆Rs are predominantly found in the primary neuronal cilia (Ruat et al., 1993; Kohen et al., 1996; Hamon et al., 1999; Berbari et al., 2008; Brodsky et al., 2017). As a G-protein coupled receptor, 5-HT₆ is positively coupled with G-proteins that stimulate production of cAMP, presumably through adenylyl cyclase III (AC3), the only adenylyl cyclase known to localize only to primary neuronal cilia (Sebben et al., 1994; Kohen et al., 2001; Kang et al., 2005; Bishop et al., 2007; Domire and Mykytyn, 2009). More recently, proteomic analysis of 5-HT₆R protein association has identified a variety of non-canonical signaling pathways, including CDK5, Fyn kinase, Jab1 and mTOR (Yun et al., 2010; Riccioni et al., 2011; Meffre et al., 2012; Duhr et al., 2014). 5-HT₆R displays a high level of ligand-independent constitutive activity, and this was proposed to regulate cortical neuronal migration and morphology (Grimaldi et al., 1998; Romero et al., 2007; Jacobshagen, Niquille, and Chaumont-Dubel, 2014; Dayer et al., 2015). However, the mechanism by which 5-HT₆R signaling

in cilia impacts morphology is still unclear, although several recent reports have attempted to elucidate this connection. Following in utero electroporation and heterologous overexpression, 5-HT₆R overexpression induced malformations and elongation of primary neuronal cilia and inhibited dendritic outgrowth (Guadiana et al., 2013). Interestingly, in this study they also found that overexpression not only caused AC3 to be excluded from the ciliary compartment, but induced cilia branching, which is not typically observed (Guadiana et al., 2013). The same lab also found that expression of a range of mouse 5-HT₆R mutants in NIH3T3 cells, including nonfunctional mutants, all increased cilia length compared to controls (Guadiana et al., 2013). On the other hand, another study found a positive association between exogenous overexpression of human 5-HT₆R and an increase in dendritic outgrowth whereas siRNA knockdown inhibited dendritic outgrowth (Duhr et al., 2014); they concluded that the Cdk5 interaction with 5-HT₆R was responsible since inhibition of Gs-coupled cAMP signaling had no effect. Recently, in Alzheimer's mouse models, 5-HT₆ was shown to have a potential role in regulating cilia and axon initial segment morphology (Hu et al., 2017).

Of note, most of these studies interrogated 5-HT₆R function using exogenous overexpression in wildtype animals rather than modulating endogenous receptor activity, and many did not focus on 5-HT₆R localization to primary neuronal cilia. Recently, we measured the effect of specific drugs on endogenous 5-HT₆R and found that selective antagonists shortened primary cilia, while none of the drug treatments increased dendritic outgrowth (Brodsky *et al.*, 2017). During this study, we coincidentally found that increasing amounts of exogenous 5-HT₆R transfection led to drastically increased ectopic expression outside of the primary cilia. Additionally, mutations that

deleted a potential cilia targeting sequence on the third intracellular loop decreased 5-HT₆R trafficking to cilia (Berbari *et al.*, 2008; Brodsky *et al.*, 2017). However, these mutations were unable to prevent cilia targeting entirely; highlighting the robust proclivity for 5-HT₆R to traffic into primary cilia.

In the present study, we investigated the effect of 5-HT₆R localization and signaling pathways on primary cilia and dendritic morphology, systematically accounting for receptor localization within each neuron. Using primary striatal neurons cultured from 5-HT₆R-null (5-HT₆R-KO) mice (Tecott *et al.*, 2000), we found that rescue of 5-HT₆R expression was sufficient to increase cilia length and stimulate dendritic outgrowth, particularly when the receptor was restricted to primary cilia. Additionally, using a 5-HT-insensitive 5-HT₆R-mutant (D106A) and a mutant lacking the predicted Fyn Kinase binding domain (426-431del), we support the idea that 5-HT₆R-dependent kinase cascades are essential for 5-HT₆R-dependent dendritic outgrowth. We hypothesize that many of the conflicting findings regarding the interplay of 5-HT₆R with neuronal morphology might be related to heterologous overexpression and extra-ciliary mislocalization. These findings highlight the careful consideration of expression level and subcellular distribution needed when studying 5-HT₆Rs and solidifies the predicted role of 5-HT₆Rs in neuronal morphology.

MOL #111583

Materials and methods

Animals. Animal procedures were approved by the University of Washington's Institutional Animal Care and Use Committee and carried out with NIH guidelines "Principles of Laboratory Animal Care" (NIH publication No. 86-23, 1996). 5-HT₆KO mice on a C57BL/6 background were a generous gift provided by Dr. Lawrence Tecott (Bonasera *et al.*, 2006). Breeding and genotyping of mice were carried out as previously described (Brodsky *et al.*, 2017).

Cell culture. Primary dissociated striatal cultures were generated from postnatal day 0-1 5-HT₆KO mice from both sexes. Crude membranes were removed prior to dissection and separation of striatum and cortical hemispheres. We and others have found that striatal neurons survive in primary culture longer when co-cultured with a small number of cortical neurons (10% cortical and 90% striatal). Minced cortical and striatal tissues were dissociated independently using papain (Sigma-Aldrich, St. Louis, MO) and trituration through a fire-polished glass pipette. Cells were plated at a density of 7×10^4 cells per cm² in culture dishes pre-coated with poly-L-lysine (Sigma; molecular weight 300,000). Cultures were maintained in Growth Media (GM) consisting of Neurobasal A (NBA) medium (Life Technologies, Carlsbad, CA) supplemented with B27 and Glutamax (1X, Life Technologies) throughout treatment days. From the fourth day in vitro (DIV) until homogenization or fixation, culture media was supplemented with 1µM Ara-C (Sigma). This culturing method was adapted from previously described methods (Lesiak et al., 2015; Brodsky et al., 2017), and result in cultures consisting of approximately 70% neurons and 30% glia. Of note, glia cells have been shown not to express significant levels of 5-HT6R mRNA and were thus not imaged or included in our

analysis (Gokce *et al.*, 2016). Cultures were maintained at 37°C under 5% CO₂ from DIV0 until homogenization or fixation.

Plasmids/Transfection. The hemagglutinin (HA)-tagged rat 5-HT₆R (Brodsky *et al.*, 2017)) was used as the wild-type receptor from which the following mutants were generated: HA-5-HT₆^{D106A} (single base pair substitution) and HA-5-HT₆^{406-411del} (removal of base pairs corresponding to PPPPTR, amino acids 406-411) using Gibson Assembly Master Mix (NEB E2611S) and oligonucleotide primers (Sigma). Rat WT and Mutant 5-HT₆R plasmid maps can be found at Neumaier Lab Website (http://depts.washington.edu/mnsl/). Primary neuronal cultures were transfected on DIV7 using Lipofectamine 2000 as previously described (Lesiak et al., 2015; Brodsky et al., 2017), wherein transfection efficiency is about 1-10%. Total plasmid for transfections consisted of 1µg DNA/well using a standard 24-well plate, with "transfection %" representing the proportion that each plasmid constituted relative to the 1 µg total transfected per well of a 24-well plate. When included, 5-HT₆R plasmids were transfected at 15% of total transfected plasmid except in the dose-response experiments where they were transfected at a range from 0-80%. Map2B-RFP plasmid (Wayman et al., 2008) was transfected as 30% of the total transfected plasmid to mark transfected neurons, since Map2B associates with the microtubules in the somatodendritic compartment of neurons and is excluded from the axon (Wayman et al., 2006). The remaining plasmid consisted of empty vector (EV, pCAGGS from Wayman Lab) and 5-HT₆ plasmid to reach the final 100% of total transfected plasmid. Immunohistochemistry and Image Analysis. Cultured neurons were fixed on DIV10 with 32°C 4% PFA/PHEMS buffer (20 min), permeabilized with 1XPBS with 0.5% Triton-

MOL #111583

X100 (10 min), blocked with 10% BSA in 1XPBS, and stained overnight with corresponding primary antibodies diluted in 1%BSA in 1XPBS, as previously described (Brodsky et al., 2017). Primary antibodies used were anti-HA rabbit (1:1000, Cell Signaling) and anti-Arl13b (1:1000, 73-287; NeuroMab, Davis, CA). Flourescent secondary antibodies, Alexa 488 anti-rabbit and Alexa 568 anti-mouse used at a dilution of 1:4000 (Invitrogen). All antibodies were diluted in 1%BSA in 1XPBS. Coverslips were mounted using ProLong Gold Antifade media containing DAPI (Invitrogen, Carlsbad, CA). Microscopic images used for morphology were acquired on a Leica inverted widefield fluorescence microscope using Metamorph software at the University of Washington Keck Microscopy Facility. Experimenters were blind to conditions during imaging and analysis. Transfected neurons were identified and selected on each coverslip using the red channel (Map2B-RFP expression) in order to avoid bias for receptor localization (anti-HA Green) or cilia presence (anti-Arl13b FarRed). Z-stack images were z-projected and analyzed using FIJI; dendrite length and branching and cilia length was analyzed using the NeuronJ plugin. Super-resolution images were acquired using a Zeiss LSM 880 confocal microscope with the AiryScan superresolution detector and FAST module.

Drugs and Drug Treatments. The 5-HT₆-selective agonist WAY-208466 and antagonist SB-399885 (Tocris Biosciences) were used as described in (Brodsky *et al.*, 2017), and cultures were treated for 48 hrs, from DIV8-10 prior to fixation.

cAMP Accumulation Assay. cAMP accumulation assays were conducted on transfected IMCD-3 kidney cells (ATCC, Manassas, VA) as previously described (Brodsky *et al.*, 2017) following the same transfection conditions described above for

primary neuronal cultures with receptor plasmids at 15% of the total DNA. Cultured cells were treated with 5-HT₆ agonist WAY-208466 (1µM) for 10 minutes before lysis. Western Blot and Fyn-IP. HEK293 cells were plated and transfected with Lipofectamine using the same transfection and dose dependent expression as described above for primary cultures and treated with vehicle or 5-HT₆ agonist (WAY-208466, 1µM final concentration) diluted in culture media for time specified in each figure legend for the corresponding experiments. For western blot, samples were lysed using RIPA buffer supplemented containing 1:100 dilution of inhibitors for protease (Sigma P8340) and phosphatases (Calbiochem 524624), run on NuPAGE 4-12% Bis-Tris Gels (Life Sciences, NP0323) then transferred to PVDF membrane. Membranes were blocked for 1 hour with Aquablock (ab166952, Thermo Fisher) then primary antibodies were diluted in Aquablock (1:1000), and blots were incubated at 4°O/N. DyLight secondary antibodies were diluted in Aquablock 1:4000 (anti-Rabbit 800 5151S, anti-Mouse 680 5470S, Cell Signaling) for 1-2 hours. After washing, blots were scanned on an Olympus Odyssey Scanner, and blots were analyzed with Image Studio. Fyn-IP was initially conducted following the Fyn-IP protocol of (Riccioni et al., 2011) without detecting Fyn. For Fyn-IP, transfected HEK cells grown on 6-well plates were lysed in 500µl of 1X TBS with 1:100 dilution of Igepal, NaF, NaOv, protease inhibitor and phosphatase inhibitor (Sigma); a 50µl fraction of samples was saved as input. Samples were pre-incubated with 3µl of anti-Fyn antibody (Millipore MABT208) and rotated for 4 hours at 4°C. Anti-A/G magnetic beads (Pierce 88803, 100µl) were added and samples were rotated at 4°C O/N. Samples were washed with fresh lysis buffer, IP samples were eluted into RIPA buffer, and input fraction was added to RIPA buffer before being run as

other western blot samples. Primary antibodies used for western blot antigen detection were as follows: anti-HA (C294 Cell Signaling), anti- α -Tubulin (DM1A Millipore), anti-Fyn (EPR5500 Millipore), anti-phospho-Src (Tyr416) (clone 9A6 Millipore). For both Western Blot and IP experiments, total protein concentrations were normalized across conditions prior to loading into the gel using Qubit and the Qubit Protein Assay Kit (Thermo Fisher).

Data Analysis. For measurements illustrated in Figure 2, 7-8 transfected neurons on 2 coverslips (15-16 total) were imaged and analyzed at each dose of $5-HT_6$ transfection. Statistics in Figure 2 used a T-test of the slope of the regression line against a nulllinear model. For measurements illustrated in Figures 4-5, 3-6 transfected neurons from each coverslip were imaged and measurements of cilia and dendrites were averaged to generate each data point (n); 3-6 coverslips were analyzed from 8 independent cultures for each experimental condition. For Figure 6, only cultures including drug-treated conditions were included in analysis, and 3-6 neurons from 1-3 coverslips across 6 independent cultures were analyzed. For Figure 6, individual neurons were treated as single data points (n) for analysis. Average cilia length remained constant across experiments, but average dendritic length varied significantly from culture to culture; therefore, average dendritic length of empty vector (EV)-controls were normalized across cultures. Cilia length data was analyzed using the Kruskal-Wallis test with Dunn's multiple comparison post-hoc, dendritic outgrowth (total dendritic length and branches) data was analyzed using 1-way ANOVA with Bonferroni post-hoc tests, and ciliation-dependent and receptor localization-dependent dendritic length analysis was analyzed using 2-Way ANOVA. All statistics were run using GraphPad Prism or Excel

MOL #111583

software, and all statistical values for experiments can be found in (Supplemental Table

1).

MOL #111583

Results

HA-Tagged 5-HT₆R localization to primary neuronal cilia

For all experiments, primary striatal neuron cultures from 5-HT₆R-KO mice were transfected using lipofection with plasmids expressing Map2B-RFP and empty vector (pCAGGS, EV) or HA-tagged-5-HT₆Rs (Rat wild-type (WT) or mutants) on the seventh day in vitro (DIV7), fixed on DIV10, and immunostained for HA-tag and a marker for primary cilia, Arl13b. We have previously confirmed overlap of cilia staining between Arl13b and adenylyl cyclase III (AC3) in primary cultured striatal neurons (Brodsky *et al.*, 2017). Super-resolution images of transfected neurons illustrate the presence of primary neuronal cilia on 5-HT₆-KO neurons (Figure 1A,C) and heterologously expressed HAtagged receptor localizing exclusively to the Arl13b marked primary neuronal cilia (Figure 1B,D). We did not observe 5-HT₆R expression (endogenous or transfected) in cells displaying glial morphology.

Increased expression of exogenously expressed 5-HT₆R increases extra-ciliary localization and aberrant cilia lengthening

Lipofection using increasing amounts of plasmid in primary cultures has been shown to lead to increased expression of exogenous mRNA and protein (Susa *et al.*, 2008; Brodsky *et al.*, 2017). Accordingly, as the proportion of HA-5-HT₆R plasmid transfected into HEK293 cells increased (balanced by corresponding empty vector), significantly greater levels of HA-tagged-5-HT₆R protein was expressed (Figure 2A). Likewise increasing the proportional amount of HA-5-HT₆R plasmid transfected into HEK293 cells led to significant increases in levels of 5-HT₆R mRNA, while expression of

MOL #111583

a stable amount of a transfected gene (GFP-CRE) and endogenous housekeeping genes did not change from condition to condition (Figure 2B).

In primary neuronal cultures of 5-HT₆R-KO neurons, exogenously expressed HA-5-HT₆Rs localize exclusively to primary neuronal cilia in about 70% of transfected neurons; however, in some neurons, particularly those without primary cilia, the receptor is distributed throughout the entire neuron (Figure 2 C-E). In a very small minority of neurons, despite the presence of Arl13b positive cilia, the receptor was expressed throughout the cell body (Figure 2E).

Increasing amounts of HA-5-HT₆R transfected into primary neuronal cultures decreased the number of neurons with cilia-restricted HA-5-HT₆R localization but did not alter the proportion of neurons with detectable primary cilia (Figure 2F). Interestingly, we found that, with increasing amounts of transfected HA-5-HT₆R, the length of cilia-associated HA-immunostaining significantly increased in neurons in which HA-5-HT₆R was restricted to the primary cilium, while the length of the Arl13b within the cilia remained constant (Figure 2G, example neuron inset). In these cases, the cilia, as measured by HA immunostaining, was unusually long while the cilia-specific marker Arl13b was not detectable along the entire length of the presumed cilia. This may be a pathological change related to excessive 5-HT₆R trafficking and is similar to previously described effects of 5-HT₆R overexpression on cilia (Guadiana et al., 2013; Hu et al., 2017). However, we did not observe any receptor-dose effect on dendritic branching or total dendritic length, in ciliated or unciliated neurons (Figure 2H-I). In a previous study we found that the percentage of ciliated striatal neurons cultured from wild-type animals containing endogenous 5-HT₆R was about 80% (Brodsky et al., 2017). Therefore, in

subsequent experiments we decided to use a modest amount of receptor plasmid (15% of total transfected plasmid) to express exogenous receptors because this level of transfection most closely replicated normal ciliation and endogenous receptor targeting to primary cilia in WT neurons (Figure 2F).

HA-5-HT₆R mutant receptor generation

In addition to investigating wild type HA-5-HT₆R, we generated two mutants to investigate how 5-HT₆R signaling properties affect primary neuron morphology. The 5-HT₆R has extensive constitutive activity (Boess *et al.*, 2002; Jacobshagen, Niguille, and Chaumont-Dubel, 2014; Nadim et al., 2016); therefore, we generated and tested a previously described mutant receptor that is insensitive to 5-HT and other 5-HT₆R agonists yet continues to display constitutive activity after heterologous expression in cell lines (5-HT₆^{D106A}). The second mutant, 5-HT₆^{406-411del}, is predicted to interrupt 5-HT₆ signaling associated with interactions with fyn kinase (Yun et al., 2007). Compared to IMCD3 cells transfected with EV plasmid, transfection with each of these three receptors increased cAMP levels in the absence of added agonist, consistent with constitutive activity of these receptors, although only the 5-HT₆^{D106A} mutant significantly increased cAMP when compared to EV controls (Figure 3A). Treatment of cells expressing WT-5-HT₆ or 5-HT₆^(406-411del) with a 5-HT₆R agonist (WAY-208466, 1 μ M) increased cAMP levels (Figure 3B) and stimulated cAMP accumulation was blocked by the further addition of the 5-HT₆R inverse agonist SB-399885 (1µM). However, agonist treatment had no effect on cAMP levels in IMCD3 cells expressing the 5-HT6^{D106A} receptor. Unfortunately, repeated attempts to demonstrate 5-HT₆R-mediated phosphorylation of fyn kinase or 5-HT₆R co-immunoprecipitation with CDK5 using

previously published methods (Yun *et al.*, 2007; Duhr *et al.*, 2014) and several other strategies were unsuccessful (Figure 3C,D). We found that transfection with WT or mutant 5-HT₆R had no effect on Fyn expression or the phosphorylation of Fyn at Y-420, with or without agonist treatment (Figure C-D, and data not shown). Therefore, we could not confirm that the deletion of aa406-411 in the 5-HT₆^(406-411del) mutant affected fyn kinase phosphorylation or the direct interaction of 5-HT₆R with Cdk5. Additionally, we detected no difference in fyn phosphorylation, with or without agonist treatment, at low or high doses of receptor expression (Supplemental Figure 1).

5-HT6R rescue elongates primary neuronal cilia

As previously reported (Brodsky *et al.*, 2017), approximately 80% of primary striatal neurons cultured from 5-HT₆R -KO had primary cilia, similar to neurons from WT mice, and this was not altered by transfection with 15% wild-type or either of the two mutant receptors (Figure 4A). In all measured neurons, regardless of whether wild-type or mutant 5-HT₆ receptors were expressed, approximately 60-70% of neurons displayed exogenous receptor localized exclusively to the cilia (Figure 4B). In ciliated neurons under these conditions, wild-type or mutant 5-HT₆ receptors were localized exclusively to the cilia about 90% of the time (Figure 4C), highlighting the proclivity of 5-HT₆ receptors to localize to the cilia when a cilium is present. Expression of WT and both mutant 5-HT₆Rs significantly increased the length of cilia (as defined by Arl13b staining) compared to empty vector controls (Figure 4D). The length of cilia when defined by HA staining of primary cilia in neurons where HA-5-HT₆R was exclusively localized in cilia was the same as when measured by Arl13b staining (Figure 4E). These findings highlight that neurons expressing exogenous 5-HT₆R have longer cilia compared to

neurons lacking 5-HT₆R, and that this effect was not ligand-activation dependent nor requiring the presence of the predicted Fyn Kinase binding domain. Cilia in neurons transfected with the WT or 5-HT₆^{406-411del} mutants were neither longer nor shorter than those transfected with the 5-HT insensitive 5-HT₆^{D106A} mutant (Figure 4D-E).

5-HT6R rescue increases dendritic length

Map2B is exclusively localized to dendrites (Wayman *et al.*, 2012), so we cotransfected Map2B-RFP with wild-type and mutant 5-HT₆Rs and then measured dendritic morphology in the same transfected neurons used to measure cilia length and receptor localization as described above. Rescue of wild-type 5-HT₆R expression in these neurons cultured from 5-HT₆ KO mice significantly increased average total dendritic length compared to empty vector controls, without changing dendritic branching (Figure 5 A-C). This increase in average total dendritic length did not appear to depend on receptor sensitivity to 5-HT, as the 5-HT insensitive 5-HT₆^{D106A} receptor mutant still increased average dendritic length (Figure 5 A-C). On the other hand, the average dendritic length of the 5-HT₆^{406-411del} mutant was not different from negative controls (Figure 5 A-C), suggesting that constitutive activation of cAMP production is insufficient to impact dendritic outgrowth, but perhaps another signaling event that is disrupted by the deletion of residues 406-411 is involved in regulating dendritic outgrowth.

Even in transfected neurons lacking 5-HT₆R, the presence of cilia was associated with an increase in total dendritic length (Figure 5D). 5-HT₆R rescue significantly increased dendritic outgrowth compared to empty vector controls in ciliated neurons. Expression of the 5-HT₆^{406-411del} mutant had no effect on dendritic length

regardless of ciliation, but the 5-HT₆^{D106A} receptor expression, like WT 5-HT₆, significantly increased dendritic outgrowth compared to empty vector controls in ciliated neurons. Ciliation did not significantly change total dendritic length in neurons expressing WT or 5-HT₆^{406-411del} (Figure 5D), suggesting that 5-HT₆R activity altered dendritic growth whether or not the receptor was exclusively localized in cilia.

In transfected neurons with discernable cilia, we found that cilia-restricted wildtype 5-HT₆R and 5-HT₆^{D106A} expression increased total dendritic length compared to ciliated control (Figure 5E). The 5-HT₆^{406-411del} mutant receptor continued to have no effect on dendritic outgrowth regardless of localization. The 5-HT₆^{D106A} mutant, like the WT receptor, only increased dendritic outgrowth in neurons where the receptor localized exclusively to cilia (Figure 5E). Of note, due to the receptors targeting outside of the primary cilia in only ~10% of ciliated neurons the number of ciliated neurons with cellwide receptor expression included in the analysis was very low.

Pharmacological regulation of 5-HT₆R in 5-HT₆-KO neurons

In prior studies examining endogenous expression of 5-HT₆Rs in primary cultures, we observed that a 5-HT₆R-selective antagonist decreased the length of neuronal primary cilia in a dose and time-dependent manner, while selective agonists had little effect on cilia length (Brodsky *et al.*, 2017). Of note, in order to maintain primary neuronal culture integrity, cultures were grown in the presence of serum, which contains 5-HT that might potentially activate the WT and mutant 5-HT₆ receptors following transfection. In that study we did not observe agonist or antagonist effects on the average dendritic length in WT primary striatal neuron cultures (Brodsky *et al.*, 2017). Similarly, neither the selective agonist (1µM WAY-208466) nor antagonist (1µM

MOL #111583

SB-399885) significantly changed dendritic outgrowth or primary cilia length compared to vehicle controls (Figure 6), with the exception that neurons expressing WT-5-HT₆Rs treated with SB-399885 had a small but significant decrease in total dendritic length (Figure 6F). These pharmacological treatments did not change dendritic length in either ciliated or unciliated neurons. However, unciliated neurons transfected with empty vector or 5-HT₆D^{106A} had significantly shorter dendrites as compared to the corresponding ciliated neurons, replicating our results from Figure 4 (Figure 6 C and O). While there was no overall interaction between the localization of transfected receptors (inside vs. outside the cilia) with drug treatments in any cases, extra-ciliary localization of the 5-HT₆^{406-411del} and 5-HT₆D^{106A} mutants significantly decreased dendritic outgrowth (Figure 6 L and P), suggesting that the trafficking of 5-HT₆R may be an important determinant of its effects on total dendritic length.

Discussion

Our findings support several conclusions that impact the interpretation of 5-HT₆R studies. First, receptor location matters, and careful attention needs to be paid to whether 5-HT₆R are being appropriately trafficked to primary cilia, as has been well established for wild-type 5-HT₆R (Hamon et al., 1999; Brailov et al., 2000; Berbari et al., 2008)3. Second, these receptors display substantial constitutive activity (at least when ectopically localized and exogenously expressed), and this complicates the interpretation of pharmacological manipulation, emphasizing the potential importance of 5-HT₆ receptor inverse agonists for drug development (Duhr et al., 2014). Third, the extent of heterologous expression contributes to extra-ciliary localization of 5-HT₆Rs and malformation of primary cilia. This effect is potentially due to disrupted trafficking and this may in turn alter the availability of signaling partners that are generally localized to primary cilia, for example AC3 (Guadiana et al., 2013; Hu et al., 2017). Likewise, exogenous and heterologous overexpression of 5-HT₆R increases extra-ciliary targeting, and this may lead to interactions with signaling molecules that are not typical partners with 5-HT₆R within the primary cilium. Finally, the presence of cilia, and 5-HT₆R within these cilia, has important implications for the regulation of neuronal morphology.

One important finding from our study is that drastic overexpression of 5-HT₆R causes radical cilia elongation and leads to increased rates of extra-ciliary receptor trafficking and cilia malformation. Interestingly, in both the present report and Brodsky et al. 2017, ArI13b length did not change with high levels of HA-5HT₆R overexpression, but in many cases the overexpressed receptor accumulated in the cilia and dramatically extended the cilia compartment as measured by HA immunostaining. Previous studies

have observed aberrant cilia formation after overexpression (Guadiana et al., 2013; Hu et al., 2017); however these studies described extensive cilia branching but did not measure the length of a cilia marker (like Arl13b or AC3) and did not quantify the extent to which they overexpressed 5-HT₆-eGFP. As such, we used low levels of heterologous expression to rescue receptor expression in a more physiologically relevant manner. and we assessed ciliation and receptor localization in order to recapitulate endogenous receptor function. We did not demonstrate whether increased cAMP production or other signaling events mediated the increase in cilia length, as we tested mutants that interfered with ligand-mediated signaling or signaling dependent on residues 406-411. Recently, in a similar study, strong overexpression of WT 5-HT₆R stimulated cilia lengthening and branching, but 5-HT₆R mutants that were deficient in cAMP production did not induce cilia lengthening (or produce abberant cilia morphology) (Hu et al., 2017). These results are still puzzling because previous reports have observed that overexpression of both Gs- and Gi-coupled receptors (5-HT₆ and SSTR3, respectively) caused cilia elongation, while in other reports mutations affecting 5-HT₆R function had little to no impact on preventing this elongation (Guadiana et al., 2013; Hu et al., 2017). However, in these previous findings, strong overexpression of 5-HT₆ disrupted localization of other important ciliary proteins (e.g. AC3 and Arl13b), and caused cilia to branch, which is not observed naturally. We suggest that it is critical to report the rates of neuronal ciliation and whether heterologously-expressed receptors localize inside or outside of cilia when drawing conclusions about the contribution of different signaling pathways to 5-HT₆R actions in neurons. At more physiologically-relevant levels of receptor rescue, cilia were never branched, and in ciliated neurons (about 75% using

Arl13b staining as a criteria) 5-HT₆Rs overwhelmingly co-localized with Arl13b as expected (~95% of ciliated neurons).

High rates of constitutive activity of exogenously expressed 5-HT₆Rs have been reported, albeit not when localized exclusively to primarily cilia (Duhr *et al.*, 2014). This is partly due to the limitations of using biochemical measurements of cAMP in this and other reports, that cannot readily determine the rate of ciliation or fidelity of trafficking. Nevertheless, constitutive activity could potentially explain why more physiologically relevant rescue of 5-HT₆R in KO cultures increased cilia length in each of the mutations we tested, and why strong exogenous overexpression resulted in excessively long cilia. Expression of other receptors that occasionally traffic to primary cilia, like type 1 dopamine receptors, have also been associated with increased cilia length (Avasthi *et al.*, 2012; Schou *et al.*, 2015).

We found that inhibition of exogenously expressed 5-HT₆R with SB-399885 decreased cilia length in some but not all expected cases, whereas we previously observed that this antagonist shortened cilia length in wild-type mouse neurons expressing endogenous 5-HT₆R (Brodsky *et al.*, 2017). One interpretation is that SB-399885 is not a full inverse agonist in this experimental system and is unable to entirely reverse the effects of the strong expression of exogenous 5-HT₆R on cAMP or possibly other signaling pathways. Exogenous expression, even at modest levels, results in significantly more mRNA and protein production compared to endogenous expression. Additionally, since the culture media was not dialyzed, residual 5-HT present in the culture medium could have contributed to cAMP production by WT 5-HT₆R and 5-HT₆R^{406-411del} to some extent. Another interesting dimension is the impact of rescuing 5-

HT₆R at different developmental stages considering that this receptor has tremendous impacts on cell migration and maturation(Jacobshagen, Niquille, Chaumont-Dubel, *et al.*, 2014). Cultured wild-type neurons will express 5-HT6R throughout in vitro development, while in the present study 5-HT6R was only present in 5-HT6-KO neurons from DIV7-10. This difference could have led to differences in responsiveness to pharmacological manipulation at the time of drug treatment on DIV9. Finally, intense overexpression of cilia-targeted receptors may alter the biology of cilia in unpredictable manners, especially since trafficking of GPCRs in and out of the primary cilium involves a complex interaction between intraflagellar transport complexes, "BBsome" proteins that are involved in complex network of interacting proteins that continues to be elucidated (Schou *et al.*, 2015; Ye *et al.*, 2017).

Previous studies reported that exogenous overexpression of 5-HT₆Rs in NG108-15 cells and neuronal explants stimulated neurite outgrowth, while *in utero* electroporation of the receptor led to aberrant cilia formation and inhibited dendritic outgrowth (Guadiana *et al.*, 2013; Duhr *et al.*, 2014). The relevance of cilia length on neuronal physiology continues to be unclear, and we found no correlations between cilia length and dendritic morphology. On the other hand, we found that dendritic morphology was correlated with the presence of a cilium and the localization of the receptor to the cilium and that 5-HT₆R had the greatest impact on dendritic outgrowth when they were in the cilia. These findings highlight the importance of monitoring 5-HT₆ receptor localization, as we found that rescue of 5-HT₆R increased dendritic outgrowth significantly only in neurons with identifiable cilia. This effect was further amplified in neurons with the receptor exclusively localized to primary cilia (Figure 5 D-E).

Interestingly, this effect was not observed for the 5-HT₆^{406-411del} mutant receptor that deleted the predicted Fyn Kinase binding domain (Yun *et al.*, 2007), and unaffected by inhibiting ligand-dependent receptor activation with 5-HT₆^{D106A} expression. Although, we were unable to detect agonist stimulation of Fyn phosphorylation in cells expressing WT 5-HT₆R and confirm the predicted effect of deleting residues 406-411 on Fyn Kinase, this deletion may interfere with other protein interactions and signaling cascades. For example, CDK5 and ß-Arrestin association are potentially disrupted. CDK5 was previously identified as important for 5-HT₆R-dependent dendritic outgrowth and constitutive activity of 5-HT₆R (Duhr *et al.*, 2014). ß-Arrestins, particularly ß-Arrestin 2, has been shown to play an important role for trafficking activated somatostatin receptor 3 out of the cilium in neurons, so we cannot rule out the possibility that the 406-411 deletion in the c-terminal did not also affect ß-Arrestin association with 5-HT₆R (Green *et al.*, 2015).

Taken together, our findings highlight the complexity of 5-HT₆ receptor signaling on neuronal physiology and support the idea that this receptor modulates neuronal morphology. We suggest that future studies and experiments should take into consideration receptor localization and the nuances of exogenous overexpression as they seek to clarify the mechanisms underlying the role of 5-HT₆R and other proteins. It is increasingly clear that 5-HT₆ receptors are targets of promising therapeutics; however, interpretation of the mechanism by which they exert their effect on neuronal function and morphology remains elusive.

Acknowledgements

Images in Figure 1 were taken with the assistance of Fernando Mignone and

Christopher Rieken, Zeiss. Map2B-RFP and pCAGGS plasmids were kindly donated by

the laboratory of Dr. Gary A. Wayman at Washington State University.

MOL #111583

Author Contributions

Participated in Research Design: Lesiak, Brodsky, and Neumaier

Conducted Experiments: Lesiak

Contributed New Reagents or Analytic Tools: Lesiak, and Brodsky

Performed Data Analysis: Lesiak, Cohenca, and Croicu

Wrote or contributed to the writing of the manuscript: Lesiak and Neumaier

References

- Aldrin-Kirk P, Heuer A, Wang G, Mattsson B, Lundblad M, Parmar M, and Björklund T (2016) DREADD Modulation of Transplanted DA Neurons Reveals a Novel Parkinsonian Dyskinesia Mechanism Mediated by the Serotonin 5-HT6 Receptor. *Neuron* 90:1–14.
- Arnt J, Bang-Andersen B, Grayson B, Bymaster FP, Cohen MP, DeLapp NW, Giethlen B, Kreilgaard M, McKinzie DL, Neill JC, Nelson DL, Nielsen SM, Poulsen MN, Schaus JM, and Witten LM (2010) Lu AE58054 a 5-HT6 antagonist reverses cognitive impairment induced by subchronic phencyclidine in a novel object recognition test in rats. *Int J Neuropsychopharm* **13**:1021–1033.
- Avasthi P, Marley A, Lin H, Gregori-Puigjane E, Shoichet BK, Zastrow von M, and Marshall WF (2012) A Chemical Screen Identifies Class A G-Protein Coupled Receptors As Regulators of Cilia. *ACS Chem Biol* **7**:911–919.
- Berbari NF, Johnson AD, Lewis JS, Askwith CC, and Mykytyn K (2008) Identification of ciliary localization sequences within the third intracellular loop of G protein-coupled receptors. *Molecular Biology of the Cell* **19**:1540-1547.
- Bishop GA, Berbari NF, Lewis J, and Mykytyn K (2007) Type III adenylyl cyclase localizes to primary cilia throughout the adult mouse brain. *J Comp Neurol* **505**:562–571.
- Boess FG, Monsma FJ Jr., and Sleight AJ (2002) Identification of Residues in Transmembrane Regions III and VI that Contribute to the Ligand Binding Site of the Serotonin 5-HT6 Receptor. *J Neurochem* **71**:2169–2177.
- Bonasera SJ, Chu H-M, Brennan TJ, and Tecott LH (2006) A null mutation of the serotonin 6 receptor alters acute responses to ethanol. *Neuropsychopharmacology* **31**:1801–1813.
- Brailov I, Bancila M, Brisorgueil MJ, Miquel MC, Hamon M, and Vergé D (2000) Localization of 5-HT(6) receptors at the plasma membrane of neuronal cilia in the rat brain. *Brain Research* **872**:271–275.
- Brodsky M, Gibson AW, Smirnov D, Nair SG, and Neumaier JF (2016) Striatal 5-HT6 Receptors Regulate Cocaine Reinforcement in a Pathway-Selective Manner. *Neuropsychopharmacology* **41**:2377–2387.
- Brodsky M, Lesiak AJ, Croicu A, Cohenca N, Sullivan JM, and Neumaier JF (2017) 5-HT6 receptor blockade regulates primary cilia morphology in striatal neurons. *Brain Research* **1660**:10–19.
- Carr GV, Schechter LE, and Lucki I (2010) Antidepressant and anxiolytic effects of selective 5-HT6 receptor agonists in rats. *Psychopharmacology* **213**:499–507.

- Dayer AG, Jacobshagen M, Chaumont-Dubel S, and Marin P (2015) The 5-HT6 receptor: a new player controlling the development of neural circuits. *ACS Chem Neurosci* **6**:951-960.
- Domire JS, and Mykytyn K (2009) Markers for neuronal cilia. *Methods Cell Biol* **91**:111–121.
- Duhr F, Déléris P, Raynaud F, Séveno M, Morisset-Lopez S, Mannoury la Cour C, Millan MJ, Bockaert J, Marin P, and Chaumont-Dubel S (2014) Cdk5 induces constitutive activation of 5-HT6 receptors to promote neurite growth. *Nat Chem Biol* 10:590–597.
- East SZ, Burnet PWJ, Leslie RA, Roberts JC, and Harrison PJ (2002) 5-HT6 receptor binding sites in schizophrenia and following antipsychotic drug administration: autoradiographic studies with [125I]SB-258585. *Synapse* **45**:191–199.
- Ferguson SM, Mitchell ES, and Neumaier JF (2008) Increased Expression of 5-HT6 Receptors in the Nucleus Accumbens Blocks the Rewarding But Not Psychomotor Activating Properties of Cocaine. *Biological Psychiatry* **63**:207–213.
- Fuchs JL, and Schwark HD (2004) Neuronal primary cilia: a review. *Cell Biology International* **28**:111-118.
- Gazea M, Tasouri E, Heigl T, Bosch V, Tucker KL, and Blaess S (2016) Definition of a critical spatiotemporal window within which primary cilia control midbrain dopaminergic neurogenesis. *Neurogenesis (Austin)* **3**:e1248206.
- Gokce O, Stanley GM, Treutlein B, Neff NF, Camp JG, Malenka RC, Rothwell PE, Fuccillo MV, Südhof TC, and Quake SR (2016) Cellular Taxonomy of the Mouse Striatum as Revealed by Single-Cell RNA-Seq. *Cell Rep* **16**:1126–1137.
- Green JA, and Mykytyn K (2014) Neuronal primary cilia: an underappreciated signaling and sensory organelle in the brain. *Neuropsychopharmacology* **39**:244–245.
- Green JA, Schmid CL, Bley E, Monsma PC, Brown A, Bohn LM, and Mykytyn K (2015) Recruitment of β-arrestin into Neuronal Cilia Modulates Somatostatin Receptor Subtype 3 Ciliary Localization. *Molecular and Cellular Biology* **36**:223-235.
- Grimaldi B, Bonnin A, Fillion M-P, Ruat M, Traiffort E, and Fillion G (1998) Characterization of 5-ht6 receptor and expression of 5-ht6 mRNA in the rat brain during ontogenetic development. *Naunyn Schmiedebergs Arch Pharmacol* **357**:393– 400.
- Guadiana SM, Semple-Rowland S, Daroszewski D, Madorsky I, Breunig JJ, Mykytyn K, and Sarkisian MR (2013) Arborization of dendrites by developing neocortical neurons is dependent on primary cilia and type 3 adenylyl cyclase. *Journal of Neuroscience* **33**:2626–2638.

- Hamon M, Doucet E, Lefèvre K, Miquel MC, Lanfumey L, Insausti R, Frechilla D, Del Rio J, and Vergé D (1999) Antibodies and antisense oligonucleotide for probing the distribution and putative functions of central 5-HT6 receptors. *Neuropsychopharmacology* 21:68–76.
- Hirst WD, Abrahamsen B, Blaney FE, Calver AR, Aloj L, Price GW, and Medhurst AD (2003) Differences in the central nervous system distribution and pharmacology of the mouse 5-hydroxytryptamine-6 receptor compared with rat and human receptors investigated by radioligand binding, site-directed mutagenesis, and molecular modeling. *Mol Pharmacol* **64**:1295–1308.
- Hirst WD, Stean TO, Rogers DC, and Sunter D (2006) SB-399885 is a potent, selective 5-HT 6 receptor antagonist with cognitive enhancing properties in aged rat water maze and novel object recognition models. Eur J Pharmacol **553**:109-119.
- Hu L, Wang B, and Zhang Y (2017) Serotonin 5-HT6 receptors affect cognition in a mouse model of Alzheimer's disease by regulating cilia function. *Alzheimers Res Ther* **9**:76.
- Jacobshagen M, Niquille M, Chaumont-Dubel S, Marin P, and Dayer A (2014) The serotonin 6 receptor controls neuronal migration during corticogenesis via a ligand-independent Cdk5-dependent mechanism. *Development* **141**:3370–3377.
- Kang H, Lee WK, Choi YH, Vukoti KM, Bang WG, and Yu YG (2005) Molecular analysis of the interaction between the intracellular loops of the human serotonin receptor type 6 (5-HT6) and the α subunit of GS protein. *Biochemical and Biophysical Research Communications* **329**:684–692.
- King MV, Spicer CH, Sleight AJ, Marsden CA, and Fone KCF (2008) Impact of regional 5-HT depletion on the cognitive enhancing effects of a typical 5-ht6 receptor antagonist, Ro 04-6790, in the Novel Object Discrimination task. *Psychopharmacology* **202**:111–123.
- Kohen R, Fashingbauer LA, Heidmann DEA, Guthrie CR, and Hamblin MW (2001) Cloning of the mouse 5-HT6 serotonin receptor and mutagenesis studies of the third cytoplasmic loop. *Molecular Brain Research* **90**:110–117.
- Kohen R, Metcalf MA, Khan N, Druck T, Huebner K, Lachowicz JE, Meltzer HY, Sibley DR, Roth BL, and Hamblin MW (1996) Cloning, Characterization, and Chromosomal Localization of a Human 5-HT6 Serotonin Receptor. *J Neurochem* **66**:47–56.
- Lee JE, and Gleeson JG (2011) Cilia in the nervous system: linking cilia function and neurodevelopmental disorders. *Curr Opin Neurol* **24**:98–105.
- Lesiak AJ, Brodsky M, and Neumaier JF (2015) RiboTag is a flexible tool for measuring the translational state of targeted cells in heterogeneous cell cultures. *BioTechniques* **58**:308–317.

- Louvi A, and Grove EA (2011) Cilia in the CNS: The Quiet Organelle Claims Center Stage. *Neuron* **69**:1046–1060.
- M W J de Bruin N, and G Kruse C (2015) 5-HT6 Receptor Antagonists: Potential Efficacy for the Treatment of Cognitive Impairment in Schizophrenia. Current Pharmaceutical Design **21**:3739-3759.
- Meffre J, Chaumont-Dubel S, Mannoury la Cour C, Loiseau F, Watson DJG, Dekeyne A, Séveno M, Rivet J-M, Gaven F, Déléris P, Hervé D, Fone KCF, Bockaert J, Millan MJ, and Marin P (2012) 5-HT(6) receptor recruitment of mTOR as a mechanism for perturbed cognition in schizophrenia. *EMBO Mol Med* **4**:1043–1056.
- Mitchell ES, and Neumaier JF (2005) 5-HT6 receptors: a novel target for cognitive enhancement. *Pharmacology and Therapeutics* **108**:320–333.
- Morairty SR, Hedley L, Flores J, Martin R, and Kilduff TS (2008) Selective 5HT2A and 5HT6 receptor antagonists promote sleep in rats. *Sleep* **31**:34–44.
- Nadim WD, Chaumont-Dubel S, Madouri F, Cobret L, De Tauzia M-L, Zajdel P, Bénédetti H, Marin P, and Morisset-Lopez S (2016) Physical interaction between neurofibromin and serotonin 5-HT6 receptor promotes receptor constitutive activity. *P Natl Acad Sci Usa* **113**:12310–12315.
- Pazour GJ, and Bloodgood RA (2008) Chapter 5 Targeting Proteins to the Ciliary Membrane, in *Current Topics in Developmental Biology* pp 115–149.
- Riccioni T, Bordi F, Minetti P, Spadoni G, Yun H-M, Im B-H, Tarzia G, Rhim H, and Borsini F (2011) ST1936 stimulates cAMP, Ca2+, ERK1/2 and Fyn kinase through a full activation of cloned human 5-HT6 receptors. *European Journal of Pharmacology* **661**:8–14.
- Romero G, Pujol M, Pérez P, Buschmann H, and Pauwels PJ (2007) Whole spectrum analysis of ligand efficacy at constitutively active human wild-type and S267K 5-HT6 receptors in HEK-293F cells. *Journal of Pharmacological and Toxicological Methods* **55**:144–150.
- Ruat M, Traiffort E, Arrang JM, Tardivel-Lacombe J, Diaz J, Leurs R, and Schwartz JC (1993) A novel rat serotonin (5-HT6) receptor: molecular cloning, localization and stimulation of cAMP accumulation. *Biochemical and Biophysical Research Communications* **193**:268–276.
- Schmidt SD, Furini CRG, Zinn CG, Cavalcante LE, Ferreira FF, Behling JAK, Myskiw JC, and Izquierdo I (2017) Modulation of the consolidation and reconsolidation of fear memory by three different serotonin receptors in hippocampus. *Neurobiology of Learning and Memory* **142**:48–54.
- Schou KB, Pedersen LB, and Christensen ST (2015) Ins and outs of GPCR signaling in primary cilia. *EMBO Rep* **16**:1099–1113.

- Sebben M, Ansanay H, Bockaert J, and Dumuis A (1994) 5-HT6 receptors positively coupled to adenylyl cyclase in striatal neurones in culture. *Neuroreport* **5**:2553.
- Singla V (2006) The Primary Cilium as the Cell's Antenna: Signaling at a Sensory Organelle. *Science* **313**:629–633.
- Stepanek L, and Pigino G (2016) Microtubule doublets are double-track railways for intraflagellar transport trains. *Science* **352**:721–724.
- Susa T, Kato T, and Kato Y (2008) Reproducible transfection in the presence of carrier DNA using FuGENE6 and Lipofectamine2000. *Mol Biol Rep* **35**:313–319.
- Tecott LH, Brennan TJ, The Regents of The University Of California (2000) Serotonin 5-HT6 receptor knockout mouse, US Patent Office.
- Trulioff A, Ermakov A, and Malashichev Y (2017) Primary Cilia as a Possible Link between Left-Right Asymmetry and Neurodevelopmental Diseases. *Genes* **8**:48.
- Valente EM, Rosti RO, and Gibbs E (2013) Primary cilia in neurodevelopmental disorders. *Nature Reviews* Neurology **10:**27-36.
- Wayman GA, Davare M, Ando H, Fortin D, Varlamova O, Cheng HY, Marks D, Obrietan K, Soderling TR, Goodman RH, and Impey S (2008) An activity-regulated microRNA controls dendritic plasticity by down-regulating p250GAP. *P Natl Acad Sci Usa* 105:9093–9098.
- Wayman GA, Impey S, Marks D, Saneyoshi T, Grant WF, Derkach V, and Soderling TR (2006) Activity-dependent dendritic arborization mediated by CaM-kinase I activation and enhanced CREB-dependent transcription of Wnt-2. *Neuron* **50**:897– 909.
- Wayman GA, Yang D, Bose DD, Lesiak A, Ledoux V, Bruun D, Pessah IN, and Lein PJ (2012) PCB-95 promotes dendritic growth via ryanodine receptor-dependent mechanisms. *Environ Health Perspect* **120**:997–1002.
- Wesolowska A, and Nikiforuk A (2007) Effects of the brain-penetrant and selective 5-HT6 receptor antagonist SB-399885 in animal models of anxiety and depression. *Neuropharmacology* **52**:1274-1283.
- Ye F, Nager AR, and Nachury MV (2017) BBSome trains remove activated GPCRs from cilia by enabling passage through the transition zone. J Cell Biol 1–58 doi:10.1083/jcb.201709041.
- Yun H-M, Kim S, Kim H-J, Kostenis E, Kim JI, Seong JY, Baik J-H, and Rhim H (2007) The novel cellular mechanism of human 5-HT6 receptor through an interaction with Fyn. *J Biol Chem* **282**:5496–5505.

Yun HM, Baik JH, Kang I, Jin C, and Rhim H (2010) Physical Interaction of Jab1 with Human Serotonin 6 G-protein-coupled Receptor and Their Possible Roles in Cell Survival. *Journal of Biological Chemistry* **285**:10016–10029.

Footnotes

Work was supported in part by the National Institute on Drug Abuse (NIDA) DA035577,

and the estate of Daniel Davis, as well as NIDA Training Grant 2T32DA00727821.

MOL #111583

Figure 1: Rescued 5-HT₆R localizes to the primary cilium in 5-HT₆R-KO neurons.

Super-resolution images taken on Zeiss LSM 880 with Airyscan of primary striatal/cortical primary neuronal cultures. Primary cultures from 5-HT₆R-KO mice were transfected with 30% Map2B-RFP (Red) \pm A) Empty Vector or B) 15% WT-HA-5-HT₆ receptor plasmid, fixed and imaged. C-D) XYZ projected images demonstrating co-localization of 5-HT₆R (Green) with ArI13B (cilia marker magenta) on the primary neuronal cilium.

Figure 2: Dose-dependent receptor expression alters 5-HT₆ receptor localization

to primary cilia. A) Graph and representative Western Blot of HEK 293 cells transfected with increasing amount of total transfected plasmid demonstrating plasmid dose dependent increase of exogenous protein expression. n=1 sample per concentration of 5-HT₆. B) Graph of qPCR data of mRNA expression following HEK 293 cells transfected with increasing % of total transfected plasmid and 15% transfection of GFP-CRE demonstrating increased expression of exogenous mRNA with increased plasmid transfection (GFP-CRE plasmid used to represent stable expression pattern of other exogenously expressed mRNA and HPRT and ß-Actin mRNA used as housekeeping genes); n=3 samples per concentration of 5-HT₆. (C-I) Primary neuronal cultures from 5-HT₆R-KO mice were transfected on DIV7 with 30% Map2B-RFP (Red) ± varying doses of HA-WT-5-HT₆R plasmid and on DIV 10, they were fixed, mounted, then imaged. C-E) Representative images of HA-WT-5-HT₆R localization in 5-HT₆R-KO primary neurons depicting C) localization of receptor to primary cilium, D) ectopic localization of receptor in neurons without primary cilium, and E) ectopic localization of

receptor in neurons with a primary cilium. F) Graph depicting plasmid dose-dependent changes in % of transfected neurons with cilia, % of transfected neurons with receptor exclusively localized to cilia, and % of ciliated transfected neurons in which the receptor localized exclusively to cilia. Red dashed line represents % of neurons with cilia in WT cultures (Brodsky et al., 2017). G) Graph depicting average cilia length in transfected neurons as determined by HA and ArI13B staining (inset representative image of extreme cilium lengthening and ArI13B exclusion at high doses of HA-5-HT₆R expression). H) Graph depicting average number of dendritic branches and average total dendritic length of transfected neurons at each receptor dose. I) Graph depicting average total dendritic length of ciliated and unciliated transfected neurons at each receptor dose. For F-I, n=15-16 neurons/condition. All statistical measures used t-test on the slope of the regression line against a null-linear model.

Figure 3: Signaling properties of 5-HT₆ Receptor Mutants. IMCD3 cells were transfected with empty vector \pm 5-HT₆R plasmid (WT-5-HT₆R, 5-HT₆R^{D106A}, 5-HT₆R^{del406-⁴¹¹) and treated with vehicle, 1µM WAY-208466 (agonist), or 1µM SB-399885 (antagonist), or 1µM of both drugs before cell lysis and tissue harvest for cAMP assay. A) Absolute cAMP levels and (B) cAMP relative to corresponding vehicle controls are shown after 10 min of drug treatment. C-D) HEK 293 were transfected with empty vector \pm 5-HT₆R plasmid or mutant receptors and treated with vehicle or 1µM WAY-208466 for 15 minutes. Immunoprecipitation from cell lysates was conducted using anti-Fyn Ab, bound material was eluted, subjected to SDS-PAGE, and then immunoblotted for Fyn and phosphorylated Fyn (p-Y420). C) Representative western blot of IP isolated}

Fyn and Fyn phosphorylated at Y-420. D) Graph depicting p-Y-420 intensity/Fyn intensity. 1-Way ANOVA, n=3 biological replicates for each experiment. Bonferroni post-hoc. *p<0.05, **p<0.01, ***p<0.001 compared to EV control. \$ p<0.01 compared to receptor vehicle control.


Figure 4: 5-HT₆**R rescue elongates primary neuronal cilia.** Primary striatal/cortical co-cultures from 5-HT₆RKO pups were transfected on DIV7 with Map2B-RFP \pm 70% empty vector or 55% EV + 15% WT-5-HT₆, 5-HT₆^{406-411del}, or 5-HT₆^{D106A}. On DIV10 cultures were fixed, immunostained for ArI13B and HA, then imaged and analyzed. A) Average percentage of neurons with cilia. B) Average percentage of neurons in which the receptor is exclusively in the primary cilium. C) Average percentage of ciliated neurons in which the receptor is exclusively in the primary cilium. D) Average cilia length. E) Average HA length. Statistical analysis was conducted using Kruskal-Wallis and Dunn's multiple comparison post-hoc. Data measured from 3-6 neurons per coverslip and pooled into a single data point. 3-6 coverslips were analyzed across 8 experiments (n coverslips, n=EV-31, WT-32, 5-HT₆^{406-411del}-31, 5-HT₆^{D106A}-33). *p<0.05, **p<0.01, ***p<0.001.


Figure 5: 5-HT₆**R rescue increases dendritic length.** Primary striatal/cortical cocultures from 5-HT₆R KO pups were transfected on DIV7 with Map2B-RFP \pm 70% empty vector or 55% EV + 15% WT-5-HT₆, 5-HT₆^{406-411del}, or 5-HT₆^{D106A}. On DIV10 cultures were fixed, immunostained for ArI13B and HA-tag then imaged and analyzed. A) Representative images of neurons transfected with different 5-HT₆ receptors and


mutants. B) Average number of dendritic branches. C) Average dendritic length. D) Average dendritic length of ciliated vs. unciliated neurons. E) Average dendritic length of ciliated neurons with and without the receptor in cilia. Data measured from 3-6 neurons per coverslip (same cells and cultures as in Figure 4) and pooled into a single data point. 3-6 coverslips were analyzed across 8 experiments. B-C) (n coverslips, n=EV-31, WT-32,5-HT₆^{406-411del}-31, 5-HT₆^{D106A}-33), 1-way ANOVA, Bonferroni post-hoc. D) n coverslips=ciliated/unciliated, EV n=30/20, WT n=29/24, 5-HT₆^{406-411del}-29/22, 5-HT₆^{D106A}-30/22), 2-way ANOVA, Bonferroni post-hoc. E) n coverslips=cilia with receptor/ cilia without receptor, EV n=0/31, WT n=27/26, 5-HT₆^{406-411del}-29/27, 5-HT₆^{D106A}-30/23). Post-hoc analysis, *p<0.05, p<0.01 compared to EV (ciliated or cilia without receptor control) and \$ p<0.05 compared to EV ciliated or EV receptor without cilia control.


Figure 6: Pharmacological regulation of 5-HT₆R in 5-HT₆-KO neurons. Primary striatal/cortical co-cultures from 5-HT₆R KO pups were transfected on DIV7 with Map2B-RFP \pm 70% empty vector or 55% EV + 15% WT-5-HT₆, 5-HT₆^{406-411del}, or 5-HT₆^{D106A}. On DIV9 cultures were treated with vehicle, either 1µM WAY-208466 (agonist) or 1µM SB-399885 (antagonist), or 1µM of both drugs until DIV 10 when cultures were fixed, immunostained for ArI13B and HA-tag then imaged and analyzed. For analysis, 3-6 neurons individual neurons were measured from 1-3 coverslips across 6 independent experiments, statistical analysis on cilia was completed using Kruskal-Wallis with Dunn's multiple comparison posthoc, on dendrites 1-way ANOVA with Bonferroni posthoc, and on dendritic measures separating cilia and receptor localization 2-way ANOVA with Bonferronni posthoc. For average cilia length and dendritic length, n=

neurons, A,B) Empty Vector, n=103,52,45,45. E,F) WT-5-HT6R, n=120, 48, 47,39. I,J) $5-HT_{6}^{406-411del}$, n=115, 42, 39, 31. M,N) $5-HT_{6}^{D106A}$, n= 123, 48, 40, 42. For effect of cilium presence on dendritic length, n= neurons ciliated/unciliated C) Empty Vector, Veh: n=83/20, WAY: n=43/9, SB: n=37/8, Both: n=28/7. G) WT-5-HT₆R, Veh: n=87/33, WAY: n=36/12, SB=37/10, Both=30/9. K) $5-HT_{6}^{406-411del}$, Veh: n=91/24, WAY: n=35/7, SB: n=32/7, Both: n=22/9. O) $5-HT_{6}^{D106A}$, Veh: n=98/25, WAY: n=43/5, SB: n=32/8, Both: n=35/6. For effect of receptor localization on dendritic length, n= neurons cilia with receptor/without, D) Empty Vector H) WT-5-HT₆R, Veh: n=80/40, WAY: n=34/14, SB=32/15, Both=30/9. L) $5-HT_{6}^{406-411del}$, Veh: n=78/37, WAY: n=31/11, SB: n=29/10, Both: n=19/12. O) $5-HT_{6}^{D106A}$, Veh: n=95/28, WAY: n=39/9, SB: n=26/14, Both: n=35/6. *p<0.05, **p<0.01, ***p<0.001.

















Restoration of physiological expression of 5-HT₆ into the primary cilia of null


mutant neurons lengthens both primary cilia and dendrites.

Atom J. Lesiak, Matthew Brodsky, Nathalie Cohenca, Alex Croicu, and John F.

Neumaier

Molecular Pharmacology

Supplemental Materials



Supplemental Figure 1: 5-HT₆R dose does not affect Fyn phosphorylation in HEK **293 cells.** HEK 293 cells were transfected with empty vector, 5-HT₆R plasmid at different doses, or untransfected, then treated with vehicle or 1μM WAY-208466 for 15 minutes. Immunoprecipitation from cell lysates was conducted using anti-Fyn Ab, bound material was eluted, subjected to SDS-PAGE, and then immunoblotted for Fyn and phosphorylated Fyn (p-Y420). A) Representative western blot of IP isolated Fyn and Fyn phosphorylated at Y-420. B) Graph depicting p-Y-420 intensity/Fyn intensity. 1-Way ANOVA, n=3 biological replicates for each experiment.

Supplemental Table 1: Statistical Data for Figures

Figure 2								
	Panel	Test	Protein	n	r^2	t	df	p-value
	A	T-test on Regression Against a Null Linear Model	5-HT6	5	0.864	2.976	3	0.058
			CRE	5		0.196	3	0.856
		Test	mRNA	n	r^2	t	df	p-value
	В	T-test on Regression Against a Null Linear Model	5-HT6	3		505.613	1	0.001
			CRE	3	-0.991	-7.569	1	0.083
			ß-Actin	3		-2.134	1	0.278
			HPRT	3		0.878	1	0.541
			GFP	3		-1.344	1	0.407
	-	Test	Measure	n	r^2	t	df	p-value
	F	T-test on Regression Against a Null Linear Model	%Ciliation	6	-0.302	-0.634	4	0.561
			%Receptor in Cilia	6		-2.267	4	0.085
			%Cilia with Receptor	6		-1.657	4	0.172
	-	Test	Measure	n	r^2	t	dt	p-value
	G	T-test on Regression Against a Null Linear Model	HA Length	6		10.88	4	0.0004
			Arl13b Length	6		1.587	4 df	0.187
	н	T	Measure	n	r^2	t -0.087	dt	p-value
	н	T-test on Regression Against a Null Linear Model	Dendritic Branches	6			4	0.934
			Dendritic Length	6	-0.136	-0.275	4 df	0.796
		T	Measure	n		t		p-value
	1	T-test on Regression Against a Null Linear Model	Ciliated Dendritic Length	6		-0.196	4	0.854
			Unciliated Dendritic Length	6	0.163	0.332	4	0.756
				_				
Figure 3	Panel	Test		r 	r^2	df(treatment)	df(residual)	p-value
	A	ANOVA, Bonferroni Post-Hoc		5.327	0.7141	15		<0.0001
	В	ANOVA, Bonferroni Post-Hoc		4.263	0.666	15	32	0.000
	-		Protein					
	D	ANOVA, Bonferroni Post-Hoc	Fyn	0.908	0.284	7	16	0.524
			p-Y-420 (pFyn)	0.64	0.219	7		0.716
		1	p-Y-420/Fyn	2.075	0.475	7	16	0.107
Figure 4	Panel	Test	н	p-value				
	A	Kruskal-Wallis and Dunn's Multiple Comparison Post-hoc	2.209	0.5302	L			
	В	Kruskal-Wallis and Dunn's Multiple Comparison Post-hoc	1.043	0.5937				
	с	Kruskal-Wallis and Dunn's Multiple Comparison Post-hoc	5.767	0.0559				
	D	Kruskal-Wallis and Dunn's Multiple Comparison Post-hoc	19.35	0.0002				
	E	Kruskal-Wallis and Dunn's Multiple Comparison Post-hoc	1.449	0.4845				
					-			
Figure 5	Panel	Test		F	r^2	df(treatment)	df(residual)	p-value
	В	ANOVA, Bonferroni Post-Hoc		2.645	0.06	3	123	0.0522
	C	ANOVA, Bonferroni Post-Hoc		5.246	0.113	3	123	0.0019
		Test		F	dF	dF (residual)	% of total variance	p-value
	D	2-Way ANOVA	Interaction	2.419	3	198	3.25	0.0674
			Ciliation	5.613	1		2.51	0.0188
			Receptor Expression	4.244	3		5.69	0.0062
	E					216	2.04	
1	E	2-Way ANOVA	Interaction	2.288	3	210	2.84	0.0795
	E	2-Way ANOVA	Interaction Receptor Localization	2.288	3	210	2.84	0.0795
	C	2-Way ANOVA			1			0.0089
	E	2-Way ANOVA	Receptor Localization	6.966	1		2.88	0.0089
Figure 6	Panel	Z-Way ANOVA	Receptor Localization	6.966	1		2.88	0.0089
Figure 6 Cilia Length	Panel A		Receptor Localization Receptor Expression Receptor EV	6.966 3.896	1		2.88	0.0089
		Test	Receptor Localization Receptor Expression Receptor EV WT 5-HT ₆	6.966 3.896 H	p-value		2.88	0.0089
		Test	Receptor Localization Receptor Expression EV WT 5-HTg 5-HT, storation	6.966 3.896 H 2.645	1 3 p-value 0.482		2.88	
		Test	Receptor Localization Receptor Expression Receptor EV WT 5-HT ₆	6.966 3.896 H 2.645 5.246	p-value 0.482 0.203		2.88	0.0089
	A E I	Test	Receptor Localization Receptor Expression EV WT 5-HTg 5-HT, storation	6.966 3.896 H 2.645 5.246 0.936	p-value 0.482 0.203 0.816		2.88 4.84	0.0089
	A E I	Test Kruskal-Wallis and Dunn's Multiple Comparison Post-hoc	Receptor Localization Receptor Expression EV WT 5-HTg 5-HT, storation	6.966 3.896 H 2.645 5.246 0.936	p-value 0.482 0.203 0.816 0.37		2.88 4.84	0.0085 0.0097 p-value
Cilia Length	A E I M	Test Kruskal-Wallis and Dunn's Multiple Comparison Post-hoc Test	Receptor Localization Receptor Expression EV WT 5-HT ₆ 5-HT ₆ ⁰⁰⁶⁴¹¹⁰⁸¹ 5-HT ₆ ^{106A} EV WT 5-HT ₆	6.966 3.896 H 2.645 5.246 0.936 3.141 F	p-value 0.482 0.203 0.816 0.37 r^2		2.88 4.84 df(residual)	0.0085
Cilia Length	A E I M	Test Kruskal-Wallis and Dunn's Multiple Comparison Post-hoc Test	Receptor Localization Receptor Expression EV VT 5-HT6 5-HT6*006A EV EV VT 5-HT6 6-HT76*006A EV VT 5-HT6 6-HT76*006A	6.966 3.896 4 2.645 5.246 0.936 3.141 F 3.063	1 3 p-value 0.482 0.203 0.816 0.37 r^2 0.0384		2.88 4.84 df(residual) 231	0.0085 0.0097 p-value 0.028
Cilia Length	A E I M	Test Kruskal-Wallis and Dunn's Multiple Comparison Post-hoc Test	Receptor Localization Receptor Expression EV WT 5-HT ₆ 5-HT ₆ ⁰⁰⁶⁴¹¹⁰⁸¹ 5-HT ₆ ^{106A} EV WT 5-HT ₆	6.966 3.896 4 2.645 5.246 0.936 3.141 F 3.063 4.674	p-value 0.482 0.203 0.816 0.37 r^2 0.0384 0.0531		2.88 4.84 df(residual) 231 250	0.0085 0.0097 p-value 0.028 0.0034
Cilia Length	A E I M B F J	Test Kruskal-Wallis and Dunn's Multiple Comparison Post-hoc Test	Receptor Localization Receptor Expression EV VT 5-HT6 5-HT6*006A EV EV VT 5-HT6 6-HT76*006A EV VT 5-HT6 6-HT76*006A	6.966 3.896 4 2.645 5.246 0.936 3.11 F 3.063 4.674 0.902	p-value 0.482 0.203 0.816 0.37 r^2 0.0384 0.0531 0.012		2.88 4.84 df(residual) 231 250 223	0.0085 0.0097 p-value 0.028 0.0034 0.4405
Cilia Length	A E I M B F J	Test Kruskal-Wallis and Dunn's Multiple Comparison Post-hoc Test ANOVA, Bonferroni Post-Hoc	Receptor Localization Receptor Expression EV VT 5-HT6 5-HT6*006A EV EV VT 5-HT6 6-HT76*006A EV VT 5-HT6 6-HT76*006A	6.966 3.896 4 2.645 5.246 0.936 3.11 F 3.063 4.674 0.902	p-value 0.482 0.203 0.816 0.37 r^2 0.0384 0.0531 0.012	df(treatment) 3 3 3 3 3 3	2.88 4.84 df(residual) 231 250 223 249	0.0085 0.0097 p-value 0.028 0.0034 0.4405 0.12
Cilia Length Dendritic Length Dendritic Length	A E I M B F J	Test Test Test Test Test Test Test Test	Receptor Localization Receptor Expression EV WT 5-HTg 5-HTg ⁴⁰⁵⁻⁴¹¹⁰⁸¹ 5-HTg ^{106A} EV WT 5-HTg 5-HTg ⁴⁰⁵⁻⁴¹¹⁰⁸¹ 5-HTg ^{106A} EV WT 5-HTg 5-HTg ⁴⁰⁵⁻⁴¹¹⁰⁸¹ 5-HTg ⁴⁰⁵⁻⁴¹¹⁰⁸¹ 5-HTg ^{106A} 5-HTg ^{106A}	6.966 3.896 2.645 5.246 0.936 3.141 F 3.063 4.674 0.902 1.958 F	p-value 0.482 0.203 0.816 0.37 r^2 0.0384 0.0531 0.012	df(treatment) 3 3 4 6 F (residual)	2.88 4.84 df(residual) 231 250 223 249 % of total variance	0.0085 0.0097 p-value 0.025 0.0034 0.4405 0.11 p-value 0.405
Cilia Length Dendritic Length	A E I M B F J	Test ANOVA, Bonferroni Post-Hoc Test EV	Receptor Localization Receptor Expression EV VT 5-HT ₆ 5-HT ₆ ⁰⁰⁶⁴¹¹⁰⁸⁰ 5-HT ₆ ⁰⁰⁶⁴¹¹⁰⁸¹	6.966 3.896 2.645 5.246 0.936 3.141 F 3.063 4.674 0.902 1.958 F 0.968	1 3 p-value 0.482 0.203 0.816 0.384 0.0531 0.012 0.023 dF 3	df(treatment) 3 3 4 6 F (residual)	2.88 4.84 df(residual) 231 230 223 249 % of total variance 1.17	0.0085 0.0097 p-value 0.028 0.0034 0.400 0.400 p-value 0.400 0.400 0.400
Cilia Length Dendritic Length Dendritic Length	A E I M B F J	Test ANOVA, Bonferroni Post-Hoc Test EV	Receptor Localization Receptor Expression EV WT 5-HT6 5-HT6 5-HT6 6-HT76 6-HT76 6-HT76 6-HT76 6-HT7606A FH7606A FH7606A 1000A 1000A 1000A Cilation	6.966 3.896 2.645 5.246 0.936 3.141 F 3.063 4.674 0.902 1.958 F 0.968 11.45	1 3 p-value 0.482 0.203 0.816 0.384 0.0531 0.012 0.023 dF 3	df(treatment) 3 3 4 6 F (residual)	2.88 4.84 df(residual) 231 250 223 249 % of total variance 1.17 4.62	0.0085 0.0097 p-value 0.028 0.0034 0.400 0.400 p-value 0.400 0.400 0.400
Cilia Length Dendritic Length Dendritic Length	A E I M B F J	Test Kruskal-Wallis and Dunn's Multiple Comparison Post-hoc ANOVA, Bonferroni Post-Hoc Test ANOVA, Bonferroni Post-Hoc EV 2-Way ANOVA	Receptor Localization Receptor Expression EV WT 5-HT6 5-HT6 5-HT6 65-HT6 65-HT6 65-HT6 65-HT6 7006A 5-HT6 5-HT6 65-HT6 66-4110el 5-HT6 1000-0004 1100-0004 1100-0004 1100-0004 Receptor Expression	6.966 3.896 2.645 5.246 0.936 3.141 F 3.063 4.674 0.902 1.958 F 0.968 11.45 2.134	1 3 p-value 0.482 0.203 0.816 0.384 0.0531 0.012 0.023 dF 3	df(treatment) 3 3 3 dF (residual) 227	2.88 4.84 df(residual) 231 250 223 249 % of total variance 1.17 4.62 2.58	0.0085 0.0097 0.0097 0.0024 0.0024 0.0024 0.0024 0.0025 0.0025 0.0006 0.0006 0.0006 0.0006 0.0006
Cilia Length Dendritic Length Dendritic Length	A E I M B F J	Test Kruskal-Wallis and Dunn's Multiple Comparison Post-hoc Fest ANOVA, Bonferroni Post-Hoc Test ANOVA, Bonferroni Post-Hoc EV 2-Way ANOVA WT 5-HT6 2-Way ANOVA	Receptor Localization Receptor Expression EV WT 5-HT ₆ 5-HT ₆ ⁰⁰⁶⁴¹¹⁰⁸¹ 6-HT ₆ ⁰⁰⁶⁴¹¹⁰⁸¹ 1nteraction Cliation Receptor Expression Interaction	6.966 3.896 2.645 5.246 0.935 3.141 F 3.063 4.674 0.902 1.958 F 0.968 1.1.45 2.134 1.45 2.234 0.299	1 3 p-value 0.482 0.203 0.816 0.384 0.0531 0.012 0.023 dF 3	df(treatment) 3 3 3 dF (residual) 227	2.88 4.84 df(residual) 231 250 223 249 % of total variance 1.17 4.62 2.28 0.35	0.0085 0.0097 0.0097 0.025 0.025 0.025 0.025 0.025 0.025 0.025 0.0400 0.0000 0.0000 0.0000 0.0000 0.025 0.0413
Cilia Length Dendritic Length Dendritic Length	A E I M B F J	Test Kruskal-Wallis and Dunn's Multiple Comparison Post-hoc Fest ANOVA, Bonferroni Post-Hoc Test ANOVA, Bonferroni Post-Hoc EV 2-Way ANOVA WT 5-HT6 2-Way ANOVA	Receptor Localization Receptor Expression EV WT 5-HT6 5-HT600411000 5-HT600411000 6-HT6004411000 5-HT6004411000 6-HT6004411000 6-HT6004411000 6-HT6004411000 6-HT6004411000 6-HT6004411000 6-HT6004411000 6-HT6004411000 6-HT60044110000 6-HT600441100000000000000000000000000000000	6.966 3.896 5.246 0.936 0.936 3.141 F 7 0.902 1.958 F 0.968 11.45 2.134 0.299 0.067	P-value 0.482 0.203 0.815 0.037 0.0384 0.0531 0.0121 0.022 dF 3 1 1 3 3 1 3 3 3 3 3 3 3 3 3 3 3 3 3	df(treatment) 3 3 3 dF (residual) 227 246	2.88 4.84 df(residual) 231 230 233 249 % of total variance 1.17 4.62 2.58 0.35 0.35 0.26	0.0085 0.0097 0.0097 0.0034 0.0034 0.0005 0.012 0.0005 0.0005 0.0005 0.0005 0.0005 0.0005 0.0005 0.01045
Cilia Length Dendritic Length Dendritic Length	A E M B F J N C C G	Test Kruskal-Wallis and Dunn's Multiple Comparison Post-hoc Fest ANOVA, Bonferroni Post-Hoc Test ANOVA, Bonferroni Post-Hoc EV 2-Way ANOVA Generalized WT 5-HT6	Receptor Localization Receptor Expression EV WT 5-HTg 5-HTg 6-HTg 1-Htraction Ciliation Receptor Expression Interaction Ciliation	6.966 3.896 H 2.645 5.246 0.936 3.063 4.674 0.902 1.958 F 2.134 0.908 11.455 2.134 0.299 0.67 2.069	1 1 3 p-value 0.4824 0.030 0.8164 0.0374 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384	df(treatment) 3 3 3 dF (residual) 227 246	2.88 4.84 d((residual) 231 250 223 % of total variance 1.17 4.62 2.58 0.35 0.26 0.26	0.0085 0.0097 0.0097 0.0026 0.0026 0.0026 0.0026 0.0026 0.0026 0.0006 0.0006
Cilia Length Dendritic Length Dendritic Length	A E M B F J N C C G	Test Kruskal-Wallis and Dunn's Multiple Comparison Post-hoc Test ANOVA, Bonferroni Post-Hoc Test Zest VIT 5-HT6 2-Way ANOVA 5-HT6_405-411dal 2-Way ANOVA	Receptor Localization Receptor Expression EV WT 5-HT ₆ 5-HT ₆ ⁰⁰⁶⁴¹¹⁰⁰¹ 5-HT ₆ ⁰⁰⁶⁴¹¹⁰⁰¹ 6-HT ₇ ^{006A} EV WT 5-HT ₆ 6-HT ₇ ^{006A} Interaction Ciliation Receptor Expression Interaction Ciliation Receptor Expression Interaction Ciliation Receptor Expression Interaction Ciliation Receptor Expression Interaction Ciliation	6.966 3.896 F 3.2645 5.2646 0.936 0.936 3.141 F 7 0.902 1.958 F 0.968 11.45 2.134 0.299 0.667 2.069 0.668	1 1 3 p-value 0.4824 0.030 0.8164 0.0374 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384 0.0384	df(treatment) 3 3 3 dF (residual) 227 246	2.88 4.84 (residual) (residual) 231 231 231 233 249 % of total variance 1.17 4.62 2.258 0.35 0.26 2.45 0.245 0.62	0.0085 0.0097 0.0097 0.0026 0.0026 0.0026 0.0026 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.00000 0.00000 0.000000
Cilia Length Dendritic Length Dendritic Length	A E M B F J N C C G	Test Kruskal-Wallis and Dunn's Multiple Comparison Post-hoc Fest ANOVA, Bonferroni Post-Hoc Test ANOVA, Bonferroni Post-Hoc EV Zway ANOVA WT 5-HT6 2-Way ANOVA 5-HT6 5-HT6	Receptor Localization Receptor Expression EV FMT_6 5-HT6 5-HT6 5-HT6 65-HT6 65-HT76 10100 65-HT76 65-HT76 10100 65-HT76 10100 65-HT76 10100 10100 10100 10100 10100 10100 10100 101000 101000 101000 101000 101000 101000 101000 101000	6.966 3.896 4 4 5.246 0.936 3.141 F 0.902 1.958 F 0.968 11.45 2.134 0.299 0.676 2.069 0.468	2 1 3 2 2 2 2 2 2 2 2 2 2 2 2 2	df(treatment) 3 3 3 dF (residual) 227 246	2.88 4.84 df(residual) 231 230 233 249 % of total variance 1.17 4.62 2.58 0.35 0.26 2.45 0.62 2.45 0.62	0.0085 0.0097 0.0097 0.0024 0.0024 0.0024 0.0026 0.0026 0.0006 0.0006 0.0006 0.0006 0.0006 0.0006 0.0403 0.0005 0.04137 0.1045 0.0704
Cilia Length Dendritic Length Dendritic Length	A E E M M B B F F J J C C C C C C C C C C C C C C C C	Test Kruskal-Wallis and Dunn's Multiple Comparison Post-hoc Test ANOVA, Bonferroni Post-Hoc Test Zest VIT 5-HT6 2-Way ANOVA 5-HT6_405-411dal 2-Way ANOVA	Receptor Localization Receptor Expression EV WT 5-HTg 5-HTg ⁰⁶⁴ 1081 5-HTg ⁰⁶⁴ 1081 5-HTg 5-HTg ^{076A} EV WT 5-HTg 5-HTg ^{076A} 5-HTg ^{076A} Interaction Ciliation Receptor Expression	6.966 3.896 5.2645 5.2646 0.936 3.141 F 3.063 4.674 0.902 1.958 F 2.134 0.968 11.165 2.134 0.968 11.252 2.134 0.677 2.069 0.468 2.972 0.965	P-value 0.482 0.203 0.816 0.037 r^2 0.034 0.0531 0.023 dF 3 3 1 1 3 3 1 3 3 3 1 3 3 3 3 3 3 3 3 3 3 3 3 3	df(treatment) 3 3 3 dF (residual) 227 246 246 219	2.88 4.84 (residual) df(residual) 231 230 233 249 % of total variance 1.17 4.62 2.58 0.35 2.45 0.26 2.45 0.62 2.45 0.62 2.131 1.32	0.0085 0.0097 0.0097 0.0026 0.0026 0.0026 0.0026 0.0006 0.0006 0.0006 0.0006 0.0006 0.0006 0.0006 0.0006 0.0006 0.0006 0.0006 0.0006 0.0006 0.0006 0.0006 0.0006 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.0007 0.000700000000
Cilia Length Dendritic Length Dendritic Length	A E E M M B B F F J J C C C C C C C C C C C C C C C C	Test Kruskal-Wallis and Dunn's Multiple Comparison Post-hoc Fest ANOVA, Bonferroni Post-Hoc Test ANOVA, Bonferroni Post-Hoc EV ZWay ANOVA WT 5-HT ₆ 2-Way ANOVA 5-HT ₆ 406-411ael 2-Way ANOVA 5-HT ₆ ^{106/A}	Receptor Localization Receptor Expression EV WT 5-HT_6 5-HT_6 ⁰⁵⁻⁴¹¹⁰⁰¹ 5-HT_6 ^{106A} EV WT 5-HT_6 5-HT_6 ⁰⁵⁻⁴¹¹⁰⁰¹ 5-HT_6 ^{106A} Interaction Cliation Receptor Expression Interaction	6.966 3.896 4 4 5.246 0.936 3.141 F 3.063 4.674 0.902 1.958 F 0.968 11.45 2.134 0.999 0.67 2.069 0.468 2.972 2.069 1.664	P-value 0.482 0.203 0.816 0.037 r^2 0.034 0.0531 0.023 dF 3 3 1 1 3 3 1 3 3 3 1 3 3 3 3 3 3 3 3 3 3 3 3 3	df(treatment) 3 3 3 3 dF (residual) 4F (residual) 227 246 229 244	2.88 4.84 (residual) 231 231 231 233 249 % of total variance 1.17 4.62 2.238 0.35 0.26 2.45 0.62 1.31 1.32 1.95	0.0085 0.0097 0.0097 0.0028 0.0028 0.0028 0.0028 0.0028 0.0028 0.0028 0.0008 0.0008 0.0008 0.0008 0.0008 0.0008 0.0008 0.0008 0.0008 0.0008 0.0008 0.0009 0.0009 0.0009 0.0009 0.0009 0.0009 0.0009 0.0009 0.0009 0.0009 0.0009 0.0009 0.0009 0.0009 0.0009 0.0009 0.0009 0.0009 0.0009 0.0009 0.0009 0.0009 0.0009 0.0009 0.0009 0.0009 0.0009 0.0009 0.0009 0.0009 0.0009 0.0009 0.0009 0.0009 0.0009 0.0009 0.0009 0.0009 0.0009 0.0009 0.0009 0.0009 0.0009 0.0009 0.0009 0.0009 0.0009 0.0009 0.0009 0.0009 0.0009 0.0009 0.0009 0.0009 0.0009 0.0009 0.0009 0.0009 0.0009 0.0009 0.0009 0.0009 0.0009 0.0009 0.0009 0.0009 0.0009 0.0009 0.0009 0.0009 0.0009 0.0009 0.0009 0.0009 0.0009 0.0009 0.0009 0.0009 0.0009 0.0009 0.0009 0.0009 0.0009 0.0009 0.0009 0.0009 0.0009 0.0009 0.0009 0.0009 0.0009 0.0009 0.0009 0.0009 0.0009 0.0009 0.0009 0.0009 0.0009 0.0009 0.0009 0.0009 0.0009 0.0009 0.0009 0.0009 0.0009 0.0009 0.0009 0.0009 0.0009 0.0009 0.0009 0.0009 0.0009 0.0009 0.0009 0.0009 0.0009 0.0009 0.0009 0.0009 0.0009 0.0009 0.0009 0.0009 0.0009 0.0000 0.0009 0.00000000
Cilia Length Dendritic Length Dendritic Length	A E E M M B B F F J J C C C C C C C C C C C C C C C C	Test Kruskal-Wallis and Dunn's Multiple Comparison Post-hoc Fest ANOVA, Bonferroni Post-Hoc Test ANOVA, Bonferroni Post-Hoc EV ZWay ANOVA WT 5-HT ₆ 2-Way ANOVA 5-HT ₆ 406-411ael 2-Way ANOVA 5-HT ₆ ^{106/A}	Receptor Localization Receptor Expression EV WT 5-HT ₆ 5-HT ₆ ⁰⁰⁶⁴¹¹⁰⁰¹ 5-HT ₆ ⁰⁰⁶⁴¹¹⁰⁰¹ 6-HT ₇ ^{006A} EV WT 5-HT ₆ 6-HT ₇ ^{006A} FeV UV 5-HT ₆ 6-HT ₇ ^{006A} 1000 6-HT ₆ 1010 6-HT ₆ 1010 Cilation Receptor Expression Interaction Cilation Receptor Expression Interaction Cliation Receptor Expression Interaction Cliation Receptor Expression Interaction Cliation	6.966 3.896 5.246 0.936 0.936 3.141 F 7 3.063 4.674 0.992 1.958 7 0.968 11.45 2.134 0.299 0.067 2.069 0.468 2.972 2.069 0.468 2.972 2.0996	1 1 3 p-value 0.4828 0.0816 0.37 r^2 0.0384 0.033 0.012 0.012 0.023 dF 3 1 3 3 1 3 3 1 1 3 3 1 1 3 3 1 1 3 3 1 1 3 3 1 1 3 3 1 1 3 3 1 1 3 3 1 1 3 3 1 1 3 3 1 1 3 3 1 1 1 3 3 1 1 1 1 1 1 1 1 1 1 1 1 1	df(treatment) 3 3 3 3 dF (residual) 4F (residual) 227 246 229 244	2.88 4.84 df(residual) 231 230 233 249 % of total variance 1.17 4.62 2.58 0.035 0.26 2.65 0.62 1.31 1.32 1.32 1.32 1.32	0.0085 0.0097 0.0097 0.0034 0.0034 0.0005 0.0405 0.0405 0.0405 0.0405 0.04137 0.1045 0.04137 0.1045 0.704 0.0866 0.3955 0.1735 0.0135 0.0933 0.093
Cilia Length Dendritic Length Dendritic Length Ciliation Dependent	A E E M M B B F F J J C C C C C C C C C C C C C C C C	Test Kruskal-Wallis and Dunn's Multiple Comparison Post-hoc Test ANOVA, Bonferroni Post-Hoc Test Zevay ANOVA, Bonferroni Post-Hoc VIT 5-HT6 2-Way ANOVA S-HT6 2-Way ANOVA S-HT6 2-Way ANOVA 2-Way ANOVA	Receptor Localization Receptor Expression EV WT 5-HTg. 5-HTg.405-4110el 5-HTg.405-4110el 5-HTg.405-4110el 5-HTg.405-4110el 5-HTg.405-4110el 5-HTg.405-4110el 5-HTg.405-4110el 5-HTg.405-4110el 5-HTg.405-4110el 5-HTg.1050A Interaction Ciliation Receptor Expression	6.966 3.896 H 2.645 5.246 0.936 3.141 F 3.063 4.674 0.902 1.958 F 0.968 11.45 2.134 0.999 0.67 2.069 0.468 2.972 0.996 1.664 6.196 0.144 F	P-value 0.482 0.203 0.816 0.37 r^2 0.034 0.0531 0.0121 0.023 dF 3 3 1 1 3 3 1 1 3 3 4 F	df(treatment) df(treatment) 3 3 3 dF (residual) 227 246 249 249 4F (residual)	2.88 4.84 df(residual) 231 231 233 249 % of total variance 1.17 4.62 2.58 0.26 2.45 0.62 1.31 1.32 1.95 2.49 0.62 1.31 7.37 7.60 total variance	0.0085 0.0097 0.0097 0.0026 0.0026 0.0026 0.0026 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.00000 0.00000 0.000000
Cilia Length Dendritic Length Dendritic Length	A E I I M B F J N C G K O O	Test Kruskal-Wallis and Dunn's Multiple Comparison Post-hoc Test ANOVA, Bonferroni Post-Hoc EV Z-Way ANOVA WT 5-HT ₆ 2-Way ANOVA SHT ₆ 406411del 2-Way ANOVA SHT ₆ 406411del 2-Way ANOVA FHT ₆ 706A 2-Way ANOVA Fest EV	Receptor Localization Receptor Expression EV WT 5-HT ₆ 5-HT ₆ ⁰⁰⁶⁴¹¹⁰⁰¹ 5-HT ₆ ⁰⁰⁶⁴¹¹⁰⁰¹ 6-HT ₇ ^{006A} EV WT 5-HT ₆ 6-HT ₇ ^{006A} FeV UV 5-HT ₆ 6-HT ₇ ^{006A} 1000 6-HT ₆ 1010 6-HT ₆ 1010 Cilation Receptor Expression Interaction Cilation Receptor Expression Interaction Cliation Receptor Expression Interaction Cliation Receptor Expression Interaction Cliation	6.966 3.896 H 2.645 5.246 0.936 3.141 F 3.063 4.674 0.902 1.958 F 0.968 11.45 2.134 0.999 0.67 2.069 0.468 2.972 0.996 1.664 6.196 0.144 F	P-value 0.482 0.203 0.816 0.37 r^2 0.034 0.0531 0.0121 0.023 dF 3 3 1 1 3 3 1 1 3 3 4 F	df(treatment) 3 3 3 3 dF (residual) 227 246 219 219 219	2.88 4.84 df(residual) 231 231 233 249 % of total variance 1.17 4.62 2.58 0.26 2.45 0.62 1.31 1.32 1.95 2.49 0.62 1.31 7.37 7.60 total variance	0.0085 0.0097 0.0097 0.0034 0.0034 0.0005 0.0405 0.0405 0.0405 0.0405 0.04137 0.1045 0.04137 0.1045 0.704 0.0866 0.3955 0.1735 0.0135 0.0933 0.093
Cilia Length Dendritic Length Dendritic Length Ciliation Dependent Dendritic Length	A E I I M B F J N C G K O O	Test Kruskal-Wallis and Dunn's Multiple Comparison Post-hoc Fest ANOVA, Bonferroni Post-Hoc Fest ANOVA, Bonferroni Post-Hoc Fest ANOVA, Bonferroni Post-Hoc VIT 5-HT6 2-Way ANOVA	Receptor Localization Receptor Expression EV WT 5-HT6 5-HT6 5-HT6 6-HT7 6-HT8 7-H78 6-HT8 6-HT8 6-HT8 6-HT8 6-HT8 7-H78 7-H78 <td>6.966 3.896 H 2.645 5.246 0.936 3.141 F 3.063 4.674 0.902 1.958 F 0.968 11.45 2.134 0.999 0.67 2.069 0.468 2.972 0.996 1.664 6.196 0.144 F</td> <td>P-value 0.482 0.203 0.816 0.37 r^2 0.034 0.0531 0.0121 0.023 dF 3 3 1 1 3 3 1 1 3 3 4 F</td> <td>df(treatment) df(treatment) 3 3 3 dF (residual) 227 246 249 249 4F (residual)</td> <td>2.88 4.84 df(residual) 231 231 233 249 % of total variance 1.17 4.62 2.58 0.26 2.45 0.26 2.45 0.62 1.31 1.32 1.95 2.49 0.62 1.31 7.7% of total variance</td> <td>0.0088 0.0093 0.0093 0.002 0.002 0.002 0.003 0.003 0.000 0.005 0.0402 0.000 0.005 0.0403 0.005 0.0403 0.005 0.0403 0.005 0.0403 0.005 0.025 0.0193 0.0093 0.0093 0.0093 0.0093 0.0093 0.0093 0.0093 0.0093 0.0093 0.0093 0.0093 0.0093 0.0093 0.0093 0.0093 0.0093 0.0093 0.0093 0.0093 0.0093 0.0093 0.0093 0.0093 0.0093 0.0093 0.0093 0.0093 0.0093 0.0093 0.0093 0.0093 0.0093 0.0093 0.0093 0.0093 0.0093 0.0093 0.0093 0.0093 0.0093 0.0093 0.0093 0.0093 0.0093 0.0093 0.0093 0.0093 0.0093 0.0093 0.0093 0.0093 0.0093 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.000</td>	6.966 3.896 H 2.645 5.246 0.936 3.141 F 3.063 4.674 0.902 1.958 F 0.968 11.45 2.134 0.999 0.67 2.069 0.468 2.972 0.996 1.664 6.196 0.144 F	P-value 0.482 0.203 0.816 0.37 r^2 0.034 0.0531 0.0121 0.023 dF 3 3 1 1 3 3 1 1 3 3 4 F	df(treatment) df(treatment) 3 3 3 dF (residual) 227 246 249 249 4F (residual)	2.88 4.84 df(residual) 231 231 233 249 % of total variance 1.17 4.62 2.58 0.26 2.45 0.26 2.45 0.62 1.31 1.32 1.95 2.49 0.62 1.31 7.7% of total variance	0.0088 0.0093 0.0093 0.002 0.002 0.002 0.003 0.003 0.000 0.005 0.0402 0.000 0.005 0.0403 0.005 0.0403 0.005 0.0403 0.005 0.0403 0.005 0.025 0.0193 0.0093 0.0093 0.0093 0.0093 0.0093 0.0093 0.0093 0.0093 0.0093 0.0093 0.0093 0.0093 0.0093 0.0093 0.0093 0.0093 0.0093 0.0093 0.0093 0.0093 0.0093 0.0093 0.0093 0.0093 0.0093 0.0093 0.0093 0.0093 0.0093 0.0093 0.0093 0.0093 0.0093 0.0093 0.0093 0.0093 0.0093 0.0093 0.0093 0.0093 0.0093 0.0093 0.0093 0.0093 0.0093 0.0093 0.0093 0.0093 0.0093 0.0093 0.0093 0.0093 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.000
Cilia Length Dendritic Length Dendritic Length Ciliation Dependent Dendritic Length	A E I I M B F J N C G K O O	Test Kruskal-Wallis and Dunn's Multiple Comparison Post-hoc Fest ANOVA, Bonferroni Post-Hoc Fest ANOVA, Bonferroni Post-Hoc Fest ANOVA, Bonferroni Post-Hoc VIT 5-HT6 2-Way ANOVA	Receptor Localization Receptor Expression EV VT 5-HT6 5-HT6 5-HT6 5-HT6 5-HT6 5-HT7 0004 VT 5-HT6 5-HT7 0004 VT 5-HT6 5-HT7 0004 VT 5-HT6 5-HT7 0004 VT 5-HT6 5-HT7 0004 1 1 0004 1 0004 1 0004 1 0004 1 0004 </td <td>6.966 3.896 3.896 0.936 3.141 F 3.063 4.674 0.902 1.958 F 0.968 11.45 2.134 0.999 0.67 2.069 0.468 2.972 0.996 1.664 6.196 0.144 F Not capable of s</td> <td>P-value 0.482 0.203 0.816 0.37 r^2 0.034 0.0531 0.0121 0.023 dF 3 3 1 1 3 3 1 1 3 3 4 F</td> <td>df(treatment) 3 3 3 dF (residual) 227 246 249 244 dF (residual) s because Receptor</td> <td>2.88 4.84 df(residual) 231 231 233 249 % of total variance 1.17 4.62 2.58 0.26 2.45 0.26 2.45 0.62 1.31 1.32 1.95 2.49 0.62 1.31 7.7% of total variance</td> <td>0.0085 0.009 p-value 0.022 0.003 0.003 0.0404 0.003 0.0404 0.000 0.0966 0.8255 0.4133 0.1044 0.004 0.0056 0.0395 0.0170 0.0395 0.0170 0.0395 0.019 p-value 0.0202 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.0000 0.000 0.000 0.000 0.0000 0.0000 0.0</td>	6.966 3.896 3.896 0.936 3.141 F 3.063 4.674 0.902 1.958 F 0.968 11.45 2.134 0.999 0.67 2.069 0.468 2.972 0.996 1.664 6.196 0.144 F Not capable of s	P-value 0.482 0.203 0.816 0.37 r^2 0.034 0.0531 0.0121 0.023 dF 3 3 1 1 3 3 1 1 3 3 4 F	df(treatment) 3 3 3 dF (residual) 227 246 249 244 dF (residual) s because Receptor	2.88 4.84 df(residual) 231 231 233 249 % of total variance 1.17 4.62 2.58 0.26 2.45 0.26 2.45 0.62 1.31 1.32 1.95 2.49 0.62 1.31 7.7% of total variance	0.0085 0.009 p-value 0.022 0.003 0.003 0.0404 0.003 0.0404 0.000 0.0966 0.8255 0.4133 0.1044 0.004 0.0056 0.0395 0.0170 0.0395 0.0170 0.0395 0.019 p-value 0.0202 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.0000 0.000 0.000 0.000 0.0000 0.0000 0.0
Cilia Length Dendritic Length Dendritic Length Ciliation Dependent Dendritic Length	A E I I M B F J N C C G K O O J Q J J J J J J J J J J J J J J J J J J J J J J J J J J J J J J J J J J J J J	Test Kruskal-Wallis and Dunn's Multiple Comparison Post-hoc Test ANOVA, Bonferroni Post-Hoc Test ANOVA, Bonferroni Post-Hoc V Test ANOVA, Bonferroni Post-Hoc V Test Z-Way ANOVA VT 5-HT ₆ 2-Way ANOVA S-HT ₆ ^{d06411dal} 2-Way ANOVA Test EV 2-Way ANOVA Test EV 2-Way ANOVA Test EV 2-Way ANOVA WT 5-HT ₆ EV 2-Way ANOVA WT 5-HT ₆	Receptor Localization Receptor Expression EV WT 5-HT ₆ 5-HT ₆ ⁰⁰⁶⁴¹⁰⁸⁰¹ 5-HT ₆ ⁰⁰⁶⁴¹⁰⁸⁰¹ 6-HT ₇ ^{006A} EV WT 5-HT ₆ 5-HT ₆ ⁰⁰⁶⁴¹¹⁰⁸⁰ 5-HT ₆ ⁰⁰⁶⁴¹¹⁰⁸⁰ 5-HT ₆ ⁰⁰⁶⁴¹¹⁰⁸⁰ 5-HT ₆ ⁰⁰⁶⁴¹¹⁰⁸⁰ Cilation Receptor Expression Interaction Receptor Expression Interaction Receptor Expression Interaction Receptor Expression Interaction	6.966 3.896 4 4 5.2445 5.2445 3.063 4.674 0.936 1.457 2.134 0.998 1.145 2.134 0.999 0.67 2.069 0.468 2.972 0.996 6.196 6.196 6.196 6.196 6.196 6.196 6.196 6.196 6.196 6.196 6.196 6.196 6.196 6.196 6.196 6.196 6.196 6.196 6.196 6.196 6.196 6.196 6.196 6.196 6.196 6.196 6.196 6.196 6.196 6.196 6.196 6.196 6.196 6.196 6.196 6.196 6.196 6.196 6.196 6.196 6.196 6.196 6.196 6.196 6.196 6.196 6.196 6.196 6.196 6.196 6.196 6.196 6.196 6.196 6.196 6.196 6.196 6.196 6.196 6.196 6.196 6.196 6.196 6.196 6.196 6.196 6.196 6.196 6.196 6.196 6.196 6.196 6.196 6.196 6.196 6.196 6.196 6.196 6.196 6.196 6.196 6.196 6.196 6.196 6.196 6.196 6.196 6.196 6.196 6.196 6.196 6.196 6.196 6.196 6.196 6.196 6.196 6.196 6.196 6.196 6.196 6.196 6.196 6.196 6.196 6.196 6.196 6.196 6.196 6.196 6.196 6.196 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7.016 7	P-value 0.482 0.203 0.816 0.37 r^2 0.034 0.0531 0.0121 0.023 dF 3 3 1 1 3 3 1 1 3 3 4 F	df(treatment) df(treatment) 3 3 3 dF (residual) 227 246 249 249 4F (residual)	2.88 4.84 df(residual) 231 230 233 249 % of total variance 1.17 4.62 2.58 0.026 2.45 0.62 1.31 1.32 1.32 1.32 1.32 2.42 0.17 % of total variance Never in Cila	0.0085 0.009 0.009 0.022 0.030 0.4040 0.030 0.4040 0.030 0.4040 0.000 0.035 0.413 0.040 0.035 0.0413 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0
Cilia Length Dendritic Length Dendritic Length Ciliation Dependent Dendritic Length	A E I I M B F J N C C G K O O J Q J J J J J J J J J J J J J J J J J J J J J J J J J J J J J J J J J J J J J	Test Kruskal-Wallis and Dunn's Multiple Comparison Post-hoc Fest ANOVA, Bonferroni Post-Hoc Test ANOVA, Bonferroni Post-Hoc EV Zway ANOVA VT 5-HT6 Z-Way ANOVA C-Way ANOVA Z-Way ANOVA Z-Way ANOVA	Receptor Localization Receptor Expression EV WT 5-HT ₆ 5-HT ₆ ⁰⁰⁶⁴¹¹⁰⁸¹ 6-HT ₈ ⁰⁰⁶⁴¹¹⁰⁸¹ 7-HT ₈ ⁰⁰⁶⁴¹¹⁰⁸¹ 6-HT ₈ ⁰⁰⁶⁴¹¹⁰⁸¹ 7-HT ₈ ⁰⁰⁶⁴¹¹⁰⁸¹ 7-HT ₈ ⁰⁰⁶⁴¹¹⁰⁸¹ 7-HT ₈ ⁰⁰⁶⁴¹¹⁰⁸¹ 8-Receptor Expression 1 1 8 9 9 9 9 9 9 9 9 9	6.966 3.896 H 2.645 5.246 0.936 3.141 F 3.063 4.674 0.902 1.958 F 0.968 11.654 2.134 0.299 0.675 2.069 0.468 2.972 0.996 1.654 5.245 Not capable of s	P-value 0.482 0.203 0.816 0.37 r^2 0.034 0.0531 0.0121 0.023 dF 3 3 1 1 3 3 1 1 3 3 4 F	df(treatment) 3 3 3 dF (residual) 227 246 249 244 dF (residual) s because Receptor	2.88 4.84 484 487 487 487 498 499 507 507 507 507 507 507 507 507 507 507	0.0088 0.009 0.009 0.002 0.003 0.003 0.003 0.003 0.003 0.000 0.005 0.0403 0.000 0.005 0.0403 0.000 0.005 0.0403 0.005 0.0403 0.005 0.0403 0.005 0.025 0.019 0.005 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.00000000
Cilia Length Dendritic Length Dendritic Length Ciliation Dependent Dendritic Length	A E I I M B F J N C C G K O O J Q J J J J J J J J J J J J J J J J J J J J J J J J J J J J J J J J J J J J J	Test Kuskal-Wallis and Dunn's Multiple Comparison Post-hoc Image: Comparison Post-hoc Im	Receptor Localization Receptor Expression EV VT 5-HT6 5-HT6 5-HT6 5-HT6 5-HT7 5-HT7 0004 VT 5-HT6 5-HT7 0004 VT 5-HT6 5-HT7 0004 VT 5-HT6 5-HT7 0004 VT 5-HT6 5-HT7 0004 5-HT7 0104 5-HT7 0104 5-HT7 0104 5-HT7 0104 5-HT7 0104 5-HT7 0104 6-HT7 0104 0104 0104 0104 0104 0104 0104 0104 0104 0104 0104 0104 0104	6.966 3.896 3.896 9.2645 5.246 0.936 3.141 F 3.063 1.938 4.674 0.902 1.938 7 0.968 1.145 2.134 0.999 0.468 2.972 0.996 0.468 2.972 0.996 0.465 0.144 F Not capable of s 0.456 0.456 2.281	1 3 p-value 0.482 0.032 0.816 0.37 72 0.0384 0.012 0.023 0.138 dF 3 1 3 1 3 1 3 1 3 1 3 1 3 1 3 1 3 3 1 3 3 1 3 3 3 3 3 1 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3	df(treatment) 3 3 3 3 dF (residual) 227 246 4F (residual) s because Receptor 246 246	2.88 4.84 df(residual) 231 231 230 249 % of total variance 2.58 0.26 2.45 0.62 1.31 1.32 1.95 2.42 0.62 1.31 1.32 1.95 2.42 0.62 1.31 7 % of total variance Never in Cilia	0.0085 0.009 0.009 0.020 0.003 0.003 0.0404 0.003 0.0404 0.000 0.0966 0.0966 0.0395 0.4133 0.0443 0.0443 0.000 0.0395 0.0104 0.0395 0.017 0.0395 0.017 0.0395 0.017 0.0395 0.019 0.020 0.020 0.020 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.0000 0.0000 0.0000 0.000 0.000 0.000 0.000 0.0000 0.0000 0.00
Cilia Length Dendritic Length Dendritic Length Ciliation Dependent Dendritic Length	A E I I M B F J N C C G K O O J O J J J J J J J J J J J J J J J J J J J J J J J J J J J J J J J J J J J J J	Test Kruskal-Wallis and Dunn's Multiple Comparison Post-hoc Test ANOVA, Bonferroni Post-Hoc Test ANOVA, Bonferroni Post-Hoc V Test ANOVA, Bonferroni Post-Hoc V Test ANOVA, Bonferroni Post-Hoc V Test EV 2-Way ANOVA WT 5-HT ₆ 2-Way ANOVA St-HT ₆ ^{406411dal} 2-Way ANOVA EV 2-Way ANOVA WT 5-HT ₆ 2-Way ANOVA WT 5-HT ₆ 2-Way ANOVA Field EV 2-Way ANOVA State EV 2-Way ANOVA State Field EV 2-Way ANOVA State State State EV 2-Way ANOVA	Receptor Localization Receptor Expression EV WT 5-HT ₆ 5-HT ₆ ⁰⁰⁶⁴¹¹⁰⁰¹ 5-HT ₆ ⁰⁰⁶⁴¹¹⁰⁰¹ 5-HT ₆ ⁰⁰⁶⁴¹¹⁰⁰¹ 6-HT ₇ ^{0106A} EV WT 5-HT ₆ 5-HT ₆ ⁰⁰⁶⁴¹¹⁰⁰¹ 5-HT ₆ ^{0106A} Interaction Ciliation Receptor Expression Interaction Receptor Expression Interaction Receptor Expression Interaction Receptor Localization Receptor Localization Receptor Localization Receptor Localization Receptor Localization Receptor Localization	6.966 3.896 3.896 3.896 3.341 F F 3.063 4.674 0.932 1.958 F 0.988 11.45 2.134 0.999 0.667 2.059 0.468 2.972 0.996 0.468 2.972 0.996 0.464 6.164 6.164 6.164 6.164 6.164 6.1256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.257 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256	p-value 0.482 0.482 0.032 +2 0.033 0.012 0.033 0.012 0.033 0.012 0.033 0.012 0.033 0.012 0.033 0.012 0.033 0.012 0.033 0.012 0.033 0.012 0.034 0.033 0.012 0.034 0.033 0.012 0.034 0.033 0.012 0.034 0.034 0.034 0.034 0.034 0.034 0.034 0.034 0.034 0.034 0.034 0.034 0.034 0.034 0.034 0.034 0.034 0.034 0.034 0.012 0.034 0.012 0.034 0.012 0.034 0.012 0.034 0.012 0.034 0.012 0.034 0.012 0.034 0.012 0.034 0.012 0.034 0.012 0.034 0.012 0.034 0.012 0.034 0.012 0.033 0.012 0.034 0.012 0.034 0.012 0.033 0.012 0.034 0.012 0.034 0.012 0.034 0.012 0.034 0.012 0.034 0.012 0.034 0.012 0.034 0.012 0.034 0.012 0.034 0.012 0.034 0.012 0.034 0.012 0.034 0.012 0.034 0.012 0.034 0.012 0.034 0.012 0.034 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.	df(treatment) 3 3 3 3 4F (residual) 227 246 246 4F (residual) s because Receptor 246	2.88 4.84 df(residual) 231 230 249 % of total variance 3.45 0.26 2.45 0.62 1.31 1.32 1.32 0.26 2.45 0.62 1.31 1.32 1.32 0.26 2.42 0.17 % of total variance Never in Cila Never in Cila 0.54 0.54 0.54 0.44	0.0088 0.009 0.009 0.022 0.030 0.030 0.030 0.04040 0.030 0.04040 0.030 0.04040 0.030 0.04040 0.0305 0.0355 0.0355 0.0355 0.0355 0.0355 0.0355 0.0355 0.0355 0.0355 0.0355 0.0355 0.0355 0.0355 0.0355 0.0355 0.0355 0.0355 0.0355 0.0355 0.0355 0.0355 0.0355 0.0355 0.0355 0.0355 0.0355 0.0355 0.0355 0.0355 0.0355 0.0355 0.0355 0.0355 0.0355 0.0355 0.0355 0.0355 0.0355 0.0355 0.0355 0.0355 0.0355 0.0355 0.0355 0.0355 0.0355 0.0355 0.0355 0.0355 0.0355 0.0355 0.0355 0.0355 0.0355 0.0355 0.0355 0.0355 0.0355 0.0355 0.0355 0.0355 0.0355 0.0355 0.0355 0.0355 0.0355 0.0355 0.0355 0.0355 0.0355 0.0355 0.0355 0.0355 0.0355 0.0355 0.0355 0.0355 0.0355 0.0355 0.0355 0.0355 0.0355 0.0355 0.0355 0.0355 0.0355 0.0355 0.0355 0.0355 0.0355 0.0355 0.0355 0.0355 0.0355 0.0355 0.0355 0.0355 0.0355 0.0355 0.0355 0.0355 0.0355 0.0355 0.0355 0.0355 0.0355 0.0355 0.0355 0.0355 0.0355 0.0355 0.0355 0.0355 0.0355 0.0355 0.0355 0.0355 0.0355 0.0355 0.0355 0.0355 0.0355 0.0355 0.0355 0.0355 0.0355 0.0355 0.0355 0.0355 0.0355 0.0355 0.0355 0.0355 0.0355 0.0000000000
Cilia Length Dendritic Length Dendritic Length Ciliation Dependent Dendritic Length	A E I I M B F J N C C G K O O J O J J J J J J J J J J J J J J J J J J J J J J J J J J J J J J J J J J J J J	Test Kuskal-Wallis and Dunn's Multiple Comparison Post-hoc Image: Comparison Post-hoc Im	Receptor Localization Receptor Expression EV WT 5-HTg 5-HTg ⁰⁰⁶⁴¹³⁰¹ 6-HTg ⁰⁰⁶⁴¹³⁰¹ 7-HTg ⁰⁰⁶⁴¹³⁰¹ 7-HTg ⁰⁰⁶⁴¹³⁰¹ 6-HTg ⁰⁰⁶⁴¹³⁰¹ 7-HTg ⁰⁰⁶⁴¹³⁰¹ 8-Receptor Expression Interaction Receptor Expression Interaction Receptor Localization Receptor Localization Receptor Localization Receptor Localization	6.966 3.896 5.246 5.246 5.246 3.341 F 3.063 4.674 4.674 4.674 4.674 1.958 7 0.968 7 2.059 0.675 2.059 0.468 2.972 2.059 0.468 1.646 6.646 1.256 2.972 0.996 1.646 5.245 1.256 2.972 2.059 0.456 5.245 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256 1.256	p-value 0.482 0.482 0.032 +2 0.033 0.012 0.033 0.012 0.033 0.012 0.033 0.012 0.033 0.012 0.033 0.012 0.033 0.012 0.033 0.012 0.033 0.012 0.034 0.033 0.012 0.034 0.033 0.012 0.034 0.033 0.012 0.034 0.034 0.034 0.034 0.034 0.034 0.034 0.034 0.034 0.034 0.034 0.034 0.034 0.034 0.034 0.034 0.034 0.034 0.034 0.012 0.034 0.012 0.034 0.012 0.034 0.012 0.034 0.012 0.034 0.012 0.034 0.012 0.034 0.012 0.034 0.012 0.034 0.012 0.034 0.012 0.034 0.012 0.034 0.012 0.033 0.012 0.034 0.012 0.034 0.012 0.033 0.012 0.034 0.012 0.034 0.012 0.034 0.012 0.034 0.012 0.034 0.012 0.034 0.012 0.034 0.012 0.034 0.012 0.034 0.012 0.034 0.012 0.034 0.012 0.034 0.012 0.034 0.012 0.034 0.012 0.034 0.012 0.034 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.	df(treatment) 3 3 3 3 dF (residual) 227 246 4F (residual) s because Receptor 246 246	2.88 4.84 484 487 487 497 500 500 500 500 500 500 500 500 500 50	0.0085 0.0097 0.0026 0.0026 0.0026 0.0026 0.0026 0.0026 0.0006 0.0006 0.0006 0.0006 0.0006 0.0006 0.0006 0.0005 0.0035 0.0173 0.0355 0.0173 0.0355 0.0173 0.0355 0.07711 0.266 0.0795 0.0795 0.0795 0.0795 0.0795 0.0795 0.0795 0.0795 0.0795 0.0795 0.0795 0.0795 0.0795 0.0795 0.0795 0.0795 0.0795 0.0795 0.0795 0.0795 0.0795 0.0795 0.0795 0.0795 0.0795 0.0795 0.0795 0.0795 0.0795 0.0795 0.0795 0.0795 0.0795 0.0795 0.0795 0.0795 0.0795 0.0795 0.0795 0.0795 0.0795 0.0795 0.0795 0.0795 0.0795 0.0795 0.0795 0.0795 0.0795 0.0795 0.0795 0.0795 0.0795 0.0795 0.0795 0.0795 0.0795 0.0795 0.0795 0.0795 0.0795 0.0795 0.0795 0.0795 0.0795 0.0795 0.0795 0.0795 0.0795 0.0795 0.0795 0.0795 0.0795 0.0795 0.0795 0.0795 0.0795 0.0795 0.0795 0.0795 0.0795 0.0795 0.0795 0.0795 0.0795 0.0795 0.0795 0.0795 0.0795 0.0795 0.0795 0.0795 0.0795 0.0795 0.0795 0.0795 0.0795 0.0795 0.0795 0.0795 0.0795 0.0795 0.0795 0.0795 0.0795 0.0795 0.0795 0.0795 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.0775 0.
Cilia Length Dendritic Length Dendritic Length Ciliation Dependent Dendritic Length	A E I I M B F J N C C G K O O J O J J J J J J J J J J J J J J J J J J J J J J J J J J J J J J J J J J J J J	Test Kruskal-Wallis and Dunn's Multiple Comparison Post-hoc Fest ANOVA, Bonferroni Post-Hoc Test ANOVA, Bonferroni Post-Hoc Test ANOVA, Bonferroni Post-Hoc Test ANOVA, Bonferroni Post-Hoc Test ANOVA, Bonferroni Post-Hoc VIT S-HT6 2-Way ANOVA Z-Way ANOVA WIT S-HT6 2-Way ANOVA WIT S-HT6 2-Way ANOVA WIT S-HT6 2-Way ANOVA	Receptor Localization Receptor Expression EV VT 5-HT6 5-HT6 5-HT6 6-HT7 6-HT7 0004 1005 6-HT6 0015 1005 1006 1007 1008 1008 1009 1010 1011 1012 1012 1013 1014 1014 1015 1014 1014 1014 1014 1014 1014 1014 1014 1014 1014 1014 1014 1014 1014 1014 1014 1014 1014 1014 1014 1014 1014 1014 </td <td>6.966 3.896 3.896 5.246 0.936 3.141 F 3.063 1.938 4.674 0.902 1.958 7 0.968 2.134 0.909 0.468 2.2134 0.2999 0.468 2.972 0.996 0.464 6.196 0.144 F Not capable of 5 0.4456 1.256 0.4456 0.3368 6.95 0.2811 0.3368</td> <td>p-value 0.482 0.203 0.816 0.37 r^2 0.0384 0.0531 0.012 0.023 0.012 0.023 dF 3 3 3 3 3 3 4 5 4 5 4 5 4 5 4 5 4 5 4 5 4 5 4 5 5 5 5 5 5 5 5 5 5 5 5 5</td> <td>df(treatment) 3 3 3 3 dF (residual) 227 246 249 4F (residual) s because Receptor 246 246 246</td> <td>2.88 4.84 df(residual) 231 250 0 223 249 % of total variance 2.58 0.26 2.42 0.35 0.26 2.42 0.35 0.26 2.42 0.35 0.26 2.42 0.42 0.42 0.42 0.42 0.54 0.44 0.54 0.44 0.54 0.49 0.54 0.49 0.54 0.49 0.54 0.49 0.54 0.49 0.54 0.49 0.54 0.49 0.54 0.49 0.54 0.49 0.54 0.49 0.54 0.49 0.54 0.49 0.54 0.49 0.54 0.55 0.55 0.55 0.55 0.55 0.55 0.55</td> <td>0.0085 0.009 0.009 0.020 0.020 0.030 0.0404 0.030 0.0404 0.010 0.000 0.0305 0.4131 0.0404 0.000 0.0355 0.4131 0.0355 0.0131 0.0395 0.0104 0.0395 0.0104 0.020 0.0395 0.0104 0.020 0.0395 0.0104 0.003 0.0395 0.0104 0.020 0.0395 0.0104 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.</td>	6.966 3.896 3.896 5.246 0.936 3.141 F 3.063 1.938 4.674 0.902 1.958 7 0.968 2.134 0.909 0.468 2.2134 0.2999 0.468 2.972 0.996 0.464 6.196 0.144 F Not capable of 5 0.4456 1.256 0.4456 0.3368 6.95 0.2811 0.3368	p-value 0.482 0.203 0.816 0.37 r^2 0.0384 0.0531 0.012 0.023 0.012 0.023 dF 3 3 3 3 3 3 4 5 4 5 4 5 4 5 4 5 4 5 4 5 4 5 4 5 5 5 5 5 5 5 5 5 5 5 5 5	df(treatment) 3 3 3 3 dF (residual) 227 246 249 4F (residual) s because Receptor 246 246 246	2.88 4.84 df(residual) 231 250 0 223 249 % of total variance 2.58 0.26 2.42 0.35 0.26 2.42 0.35 0.26 2.42 0.35 0.26 2.42 0.42 0.42 0.42 0.42 0.54 0.44 0.54 0.44 0.54 0.49 0.54 0.49 0.54 0.49 0.54 0.49 0.54 0.49 0.54 0.49 0.54 0.49 0.54 0.49 0.54 0.49 0.54 0.49 0.54 0.49 0.54 0.49 0.54 0.49 0.54 0.55 0.55 0.55 0.55 0.55 0.55 0.55	0.0085 0.009 0.009 0.020 0.020 0.030 0.0404 0.030 0.0404 0.010 0.000 0.0305 0.4131 0.0404 0.000 0.0355 0.4131 0.0355 0.0131 0.0395 0.0104 0.0395 0.0104 0.020 0.0395 0.0104 0.020 0.0395 0.0104 0.003 0.0395 0.0104 0.020 0.0395 0.0104 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.020 0.
Cilia Length Dendritic Length Dendritic Length Ciliation Dependent Dendritic Length	A E I I M B F J N C C G K O O J O J J J J J J J J J J J J J J J J J J J J J J J J J J J J J J J J J J J J J	Test Kruskal-Wallis and Dunn's Multiple Comparison Post-hoc Test ANOVA, Bonferroni Post-Hoc Test ANOVA, Bonferroni Post-Hoc V Test ANOVA, Bonferroni Post-Hoc V Test ANOVA, Bonferroni Post-Hoc V Test EV 2-Way ANOVA WT 5-HT ₆ 2-Way ANOVA St-HT ₆ ^{406411dal} 2-Way ANOVA EV 2-Way ANOVA WT 5-HT ₆ 2-Way ANOVA WT 5-HT ₆ 2-Way ANOVA Field EV 2-Way ANOVA State EV 2-Way ANOVA State Field EV 2-Way ANOVA State State State EV 2-Way ANOVA	Receptor Localization Receptor Expression EV WT 5-HTg 5-HTg ⁰⁰⁶⁴¹³⁰¹ 6-HTg ⁰⁰⁶⁴¹³⁰¹ 7-HTg ⁰⁰⁶⁴¹³⁰¹ 7-HTg ⁰⁰⁶⁴¹³⁰¹ 6-HTg ⁰⁰⁶⁴¹³⁰¹ 7-HTg ⁰⁰⁶⁴¹³⁰¹ 8-Receptor Expression Interaction Receptor Expression Interaction Receptor Localization Receptor Localization Receptor Localization Receptor Localization	6.966 3.896 5.246 5.246 5.246 3.341 F 3.063 4.674 4.674 4.674 1.958 F 0.968 11.654 2.134 0.059 0.675 2.069 0.468 2.972 2.069 0.468 1.654 6.654 5.0144 F Not capable of s 0.0466 1.256 2.281 0.0368 0.0368 0.0368 0.0368 0.0368 0.0368	p-value 0.4828 0.4828 0.032 472 0.0384 0.033 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012 0.012	df(treatment) 3 3 3 3 dF (residual) 227 246 4F (residual) s because Receptor 246 246	2.88 4.84 484 487 487 497 500 500 500 500 500 500 500 500 500 50	0.0088 0.009 0.009 0.002 0.002 0.003 0.003 0.003 0.003 0.003 0.000 0.005 0.0403 0.000 0.005 0.0403 0.005 0.0403 0.005 0.0403 0.005 0.0403 0.005 0.025 0.0413 0.025 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.035 0.0400 0.035 0.0400 0.005 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.000 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.009 0.0

Supplemental Table 1: Table of Statistical Analysis